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Abstract 
 
Allergic contact dermatitis (ACD) is characterised by type IV 
hypersensitivity to a specific allergen and is diagnosed by patch testing, 
where allergens are placed against the skin. The ‘baseline series’ refers to a 
set of the most important allergens used as a screening series and must be 
relevant to the population tested. In 2015, an Australian baseline series (ABS) 
was proposed based on a 10-year retrospective review of patch test results in 
Victoria. The primary objective of this work was to describe patch test results 
in patients undergoing testing at The Skin Hospitals in Darlinghurst and 
Westmead in New South Wales.  
Data was retrospectively collected from The Skin Hospital’s Microsoft 
Access database from 1 January 2002 to 31 December 2016. Information 
collected included demographic details, clinical presentation and patch test 
results. The most recent ten-year period was used for most analyses to 
provide results with current relevance.  
 In the last-ten-years 1,584 patients were patch-tested at The Skin 
Hospitals in NSW. The positivity rate (proportion of patients with ≥ 1 positive 
reaction) was 27.8%. The most frequently positive allergens were nickel 
sulfate, cobalt chloride, Myroxylon pereirae (balsam of Peru), fragrance mix I 
and p-phenylenediamine (PPD). Rates of positivity to metals, 
methylchloroisothiazolinone/methylisothiazolinone, PPD, colophonium and 
Myroxylon pereirae increased in 2012-2016 compared with 2007-2011. The 
ABS detected 71.5% of positive reactions and 72.9% of relevant reactions.  
Our study had an overall lower positivity rate and lower rates of 
occupational and hand dermatitis compared with data from Victoria and 
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therefore provides useful information on the performance of the ABS in a 
general patch-testing clinic. Top allergens were in keeping with other 
Australian and International reports, with the possible exception of dodecyl 
gallate, which had more positive and relevant reactions than expected. The 
rise in nickel sensitisation, converse to some International reports, warrants 
ongoing surveillance as there is no current Australian legislation to regulate 
nickel in products contacting the skin.  
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1. Literature review  
Introduction 
Allergic contact dermatitis 
Allergic contact dermatitis (ACD) is characterised by an eczematous 
skin eruption after direct skin contact with a specific allergen (known as the 
hapten). The reaction is reproducible on repeated allergen exposure (1). The 
gold standard diagnostic tool for ACD is patch testing which involves mapped 
application of selected allergens to the skin surface and subsequent 
observation of an eczematous skin response (2).  
The mechanism of ACD is type IV hypersensitivity to a hapten that the 
patient has previously been sensitised to. Type IV hypersensitivity is also 
described as delayed-type and is mediated by T cells. Sensitisation may 
occur on first exposure to the hapten or after any number of previous 
exposures. In order for sensitisation to occur, haptens must be able to 
penetrate the top layer of the epidermis (stratum corneum) and therefore are 
of low molecular weight (almost always <500 Daltons) (3). After penetration, 
the hapten is bound by skin proteins and engulfed by resident antigen 
presenting cells, which migrate to local lymph nodes and present the hapten 
to T cells via class II major histocompatibility complexes. This process is 
known as priming and leads to production of a hapten-specific T cell 
population that can be recruited on subsequent exposure to the hapten. It 
takes approximately 7-10 days for priming to be complete (4). Upon repeated 
exposure antigen presenting cells again engulf the protein-bound hapten and 
present it to primed hapten-specific T cells in the skin leading to activation and 
 14 
release of chemokines and cytokines and up regulation of the immune 
response. Clinically an eczematous eruption is observed. This explanation is 
somewhat simplified and there are other complementary pathways to immune 
activation. As an example, there is evidence that the innate immune system 
has a role in ACD has been demonstrated in humans where nickel (known to 
cause ACD) was bound by toll-like receptors during sensitisation (5). 
Macroscopically, ACD manifests acutely as eczema at the site of 
contact with the hapten. Severity ranges from mild, patchy dermatitis to a 
severe eruption with vesicles and bullae. In the chronic phase, scaling, 
fissuring and lichenification can occur. Unfortunately, eczema is a very 
common reaction pattern of the skin. It has been reported that up to 40% of 
the adults have had eczema at some stage and that up to 20% of the 
population may suffer from atopic dermatitis (6). While atopic dermatitis is an 
endogenous cause of eczema, some patients can be sensitised to allergens 
and have a concurrent diagnosis of ACD. These cases often present with 
destabilised and recalcitrant disease. In general, most causes of eczema are 
not ACD, but ruling out ACD is always critical in these individuals, as optimal 
disease control in ACD is best achieved with allergen avoidance.  
The pattern of the eruption is often helpful in formulating a differential 
diagnosis both for the potential allergens involved and other non-allergic 
dermatoses. For example, an eruption on the eyelids may be ACD, possibly 
due to preservatives or fragrance in cosmetics or ophthalmic preparations, or 
an entirely different condition such as seborrhoeic dermatitis, rosacea, atopic 
dermatitis or psoriasis (7). Less commonly, non-eczematous manifestations 
occur as a consequence of ACD. Examples include purpuric reactions to 
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textile dyes (8), lichenoid reactions to amalgam (9) and pustular reactions to 
metal salts (10). Systemic manifestations may occur if there is exposure to a 
hapten via ingestion or inhalation in an individual with prior contact 
sensitistaion. Systemic exposure may result in flaring of eczema at the initial 
site of contact, palmoplantar dyshidrotic dermatitis or generalised eruptions 
including widespread eczema, erythema multiforme, vasculitis, urticaria or 
intertriginous rash (the so called ‘baboon syndrome’) (4). 
ACD must be differentiated from irritant contact dermatitis where a 
substance in contact with the skin causes eczema due to a chemical noxious 
effect and is not mediated by a hapten-specific T cell population. Irritant 
contact dermatitis is often dose dependent and not reliably reproducible. For 
the example given above, the eyelids are particularly susceptible to physical 
irritation from flakes of eye make-up as well as chemical irritation from 
ingredients of eye-area preparations such as sunscreen, soap emulsifiers and 
solvents (4).  
Unless the allergen is identified and avoided, ACD often runs a chronic 
course with a large impact on the patient’s quality of life. Further impact of 
ACD occurs when exposure to the hapten is in an occupational setting, where 
alteration of work duties may be inadequate to provide relief and a career 
change may be advised. Diagnosis of ACD with patch testing has been shown 
to improve disease-specific quality of life by enabling avoidance of the 
correctly identified allergen, which, in a number of cases, leads to resolution 
of disease (11). Despite this, rates of patch testing in Australia are suboptimal 
meaning that many patients with ACD never receive the correct diagnosis or 
management advice (12). 
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Patch testing methodology 
Patch testing is considered the gold standard for diagnosing ACD 
although exact sensitivity and specificity are unknown and many aspects of 
methodology remain controversial (13). The indications for patch testing 
according to the European Society of Contact Dermatitis guidelines (14) are:  
• Suspected contact dermatitis. 
• Other forms of dermatitis recalcitrant to treatment. 
• Selected presentations of mucocutaneous disease where type IV 
hypersensitivity is suspected. 
The basic principles of patch testing include the selection of appropriate 
allergens for testing, percutaneous application of selected allergens that 
remain in situ for a specified period (most often 2 days) after which they are 
removed. The testing site is then observed for development of an eczematous 
reaction over the next few days. Various allergens and allergen mixes are 
commercially available and should be selected by a specialist dermatologist 
on a case-by-case basis depending on the clinical scenario.   
Most centres utilise a range of testing ‘series’ including a standard or 
baseline series, to which the majority of patients are tested. The baseline 
series should include the most commonly positive allergens in the testing 
population and therefore varies with locality (15). Baseline series’ also usually 
include allergen mixes tested in one chamber. For example, fragrance mix I 
and II contain various mixes of the individual fragrance allergens. These 
mixes conserve testing space on the patients back and act as a screening 
test. If there is a reaction to a mix then the individual allergens can be 
subsequently tested to decipher the true reaction. Allergens in the baseline 
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series used at the Darlinghurst and Westmead testing sites in New South 
Wales (NSW) are listed in Appendix one.  
In addition to the baseline series, other relevant series may be added 
according to the clinical scenario. For example, a hairdresser with dermatitis 
on the hands may be tested to the ‘hairdressing series’ or a young woman 
with eyelid dermatitis may be tested to the ‘cosmetic series’. Examples of 
other ‘special’ series are listed in Appendix two. The patient’s own topical 
products should also be tested where relevant (16). Allergens are usually 
prepared in petrolatum or water. The concentration is also specified in order 
to maximise sensitivity, minimise irritant reactions and the possibility of 
sensitisation occurring during the patch test process.  
Once the appropriate allergens are selected the patch tests are 
manually prepared by placing the allergens into individual testing chambers. 
Various patch test chambers are available including popular Finn Chambers® 
made from aluminum. Generally test chambers come pre-mounted onto a 
tape strip for ease of application (17). The testing centres at Darlinghurst and 
Westmead use polyethylene plastic square chambers mounted on tape with a 
chamber area of 0.68cm2 (Chemotechnique IQ Ultra, Figure 1.1). These 
chambers have good documented agreement with Finn chambers (18).  
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Figure 1.1 Polyethylene plastic square testing 
chambers mounted on tape for patch testing 
(Chemotechnique IQ Ultra). Note there are ten 
chambers per strip with each chamber housing one 
allergen. 
 
 
 
 
 
An alternative to the traditional chamber testing is the Thin-layer Rapid 
Use Epicutaneous Test (TRUE test®), which comes pre-prepared and loaded 
with allergens incorporated in hydrophilic gels. Advantages of the TRUE test® 
system include a standardised machine-dispensed allergen dose and reduced 
preparation time. Reported concordance with the chamber system varies and 
this limited series may increase the likelihood of missing allergens (19, 20). 
The prepared chambers are applied to the patient’s skin and may be 
re-enforced with extra tape to ensure good adhesion. The upper back (Figure 
1.2) is the most common testing site used for practical reasons (a large 
relatively flat site with low mobility) and may reduce false-negatives as the 
back is comparatively more sensitive than the arms (21). It is crucial that 
patches are applied to intact skin free from eczema and other inflammatory 
dermatoses. The presence of these hampers interpretation of results and 
risks false positives. Further, if testing is undertaken on inflamed skin or in a 
patient with significant eczema elsewhere on the body there is a risk of the 
‘angry back syndrome’ (Figure 1.3). This term was coined in the 1970s to 
describe a patient with multiple false positive reactions on patch testing (22). 
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Application of patches directly over other skin lesions such as seborrhoeic 
keratoses, naevi and tattoos should also be avoided (17).  
The patches are left in place, usually 2 days, before removal. During 
this time the patient is instructed to keep the patches dry and avoid activity 
that may disrupt tape adhesion (such as heavy exercise and sweating). The 
first reading is generally performed after patches are removed. It is useful to 
wait 15-30 minutes before reading to allow for fading of erythema secondary 
to tape removal and pressure from the chambers. After removal the position 
of patches is recorded with a skin-marking pen such as gentian violet. 
Reactions are graded as positive, indeterminate, negative or irritant based on 
visual inspection and palpation as outlined in table 1.1. A positive patch test 
reaction is defined as a reaction of at least 1+ (14).  An example of a positive 
patch test result is shown in figure 1.4.  
 
Figure 1.2 Application of patch test chambers on the back. 
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Figure 1.3 A patient with ‘angry back syndrome’ after undergoing patch 
testing. Multiple positive reactions were seen on day 2. 
 
Table 1.1 Grading of patch test reactions according to the International 
Contact Dermatitis Research Group (23). 
Score  Interpretation 
- Negative reaction 
+- Doubtful reaction (faint or macular erythema, not counted as 
positive) 
+ Weak positive (palpable erythema, non vesicular) 
++ Strong positive (oedematous or vesicular; erythema, infiltration, 
vesicles) 
+++ Extreme positive (bullous or ulcerative) 
IR Irritant reaction of various types 
NT Not tested 
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Figure 1.4 Positive patch test result to methylisothiazolinone. This bullous 
reaction was graded as +++. 
 
Care must be taken with interpretation of the first reading. A study of 
9,945 patch tested patients showed approximately one third of positive 
reactions were not present until day 3 and 8.3% of weak reactions seen on 
day 2 faded by day 3, indicating that limiting to the first reading on day 2 may 
result in increased false negatives and false positives due to misinterpretation 
of irritant reactions (24). 
After the first reading skin markings remain in place until the second 
and main reading. The optimal timing of this is debated (13). It is most often 
done at day 3 or 4 although this varies between centres up to day 7. 
Reactions first seen at day 7 are termed late reactors and well known 
examples include nickel, cobalt, neomycin and corticosteroids (17). Reading 
at day 7 was useful in detecting reactions to metals and topical steroids in a 
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Mayo clinic study (25). However, reactions to some fragrances and 
preservatives had faded by the late reading. A German study found that 
compared with day 3, readings on day 4, 5 and 6 showed more fading 
reactions than new positives and concluded that day 3 was the best day for 
the second reading (26). However, Todd and colleagues found reading at day 
4 best, with less false positives and negatives compared with reading at day 2 
or 3 (27). The 2017 British Association of Dermatologists’ guidelines suggest 
an optimal regime with readings at day 2, 4 and 7 (2). Practically, this can be 
performed with the application of patches on Monday, removal and first 
reading on Wednesday and second reading on Friday with an optional 7-day 
reading on the following Monday. 
The relevance of positive results should be assessed by correlation 
with clinical history and examination findings (2). Positive results can be 
classified as being relevant, of past relevance or unknown relevance. A 
relevant positive result confirms the diagnosis of ACD and occurs when there 
is a history of compatible dermatitis, a history of exposure to an allergen and 
positive patch test. Past relevance is that where exposure in the past has led 
to dermatitis but exposure is not ongoing. If it is not clear if exposure is current 
or old a reaction is classified as being of unknown relevance. Reactions may 
also be seen due to cross-reaction with another, possibly relevant, allergen 
(28). Relevance can be further clarified by a repeated open application test 
(ROAT). For a ROAT a suspected product (such as leave on personal care 
product or topical medication) is applied to a defined area of skin (usually the 
inner arm) twice daily for up to two weeks with careful observation for a skin 
reaction (14). 
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Adverse effects of patch testing are rare but the patient should be 
warned of itch or discomfort resulting from a positive reaction and the risk of 
‘angry back syndrome’. Reactions are usually short-lived but may persist for 
weeks for selected allergens including gold (2). Other reported adverse 
effects include induced/novel sensitisation, type 1 hypersensitivity reactions, 
flaring of underlying atopic dermatitis and scarring from vigorous positive 
reactions (29). 
 
Patch test data reporting 
Surveillance and reporting of patch test results has an important role in 
the regulation of potential sensitisers used by product manufacturers (30). 
Results of patch testing include positive readings, assessment of relevance 
and follow-up assessments. Guidelines for the reporting and statistical 
analysis of patch test results are outlined by Uter and colleagues and 
summarized in Table 1.2 (31). The population or ‘denominator’ should be 
clearly described in terms of the number of patients tested to each allergen, 
time period and testing method used (consecutive or targeted). Testing to the 
standard series is generally consecutive with added specialised series as 
clinically indicated.  
The baseline characteristics of the population also influence results 
and should be adequately described (32) including a description of ‘case 
ascertainment’ (33). For example, are patients accepted for patch testing only 
after being seen by a specialist dermatologist or can they be referred from 
their general practitioner? Does the clinic run other specialist clinics that may 
influence the referral base, for example oral medicine or vascular surgery? 
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This selection bias will influence the frequency of positive patch testing and 
the relative frequency of each allergen. 
A positive result is defined as any reaction with a +, ++ or +++ result. 
Some authors advocate reporting + results separately or reporting the 
‘positivity ratio’ (defined as the number of + results divided by the sum of +, ++ 
and +++ results) (31). A positivity ratio of greater than 80% is suggestive of a 
problematic allergen, which is yielding irritant results and false positives. 
 
Table 1.2 Key points in reporting and statistical analysis of patch test results 
according to Uter and colleagues (31). 
Proportion 
and rates 
Report with 95% confidence intervals 
Normal approximation of the binomial distribution may be 
used as long as sample ≥ 30 
For comparison of two proportions Chi-squared test should 
be used (or Fisher’s exact test if any cell counts <5) 
For assessing trends over time Chi-squared test or 
Cochrane-Armitage test should be used 
Adjusting for 
confounding 
variables  
e.g. age and 
gender 
Restriction of study population by confounding variables 
Stratification – report results separately for subgroups 
defined by confounding variables 
Matching – outlined in study design 
Standardisation – prevalence rates reported as weighted 
sum of stratum-specific prevalences 
Multifactorial analysis – accounts for several confounding 
factors simultaneously 
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Epidemiology of allergic contact dermatitis 
Demographic factors influencing patch test results 
 Positive results on patch testing are indicative of the population being 
tested and should not be interpreted as relevant to the general population. 
Although most data originate from patients tested after presenting with a 
dermatological condition, a large cross-sectional study from Europe has 
assessed the rate of contact sensitisation in the general population (34). A 
random sample of 3,119 adults were patch tested to the European baseline 
series from a larger cohort of 12,377 people that had been randomly selected 
from electoral data. Of note, characteristics and rates of non-responders were 
not reported in this paper and participation rates (reported separately) were 
low, ranging from 20.3% to 50.7% (35). Of the 3,119 participants, 27% had at 
least one positive reaction with the most common to metals, preservatives 
and fragrances. Overall, more positive results were seen in women with an 
odds ratio of 2.6 (95% CI 2.1-3.1) for contact allergy compared with men. 
Other factors associated with a positive patch test result included a history of 
contact allergy and itchy rashes lasting 3 days or more. Atopic dermatitis and 
history of ‘sensitive skin’ were not associated with contact allergy.  
 The acronym ‘MOHL’ (standing for male sex, occupational causation, 
hand dermatitis and leg ulcer or dermatitis) was introduced in the 1970s to 
describe demographic factors influencing the relative frequency of positive 
results at any testing centre (36). This was later revised to ‘MOAHL’ including 
atopy (37), and again in the 1990s to ‘MOAHLFA’ adding facial dermatitis, age 
>40 years and altering the general definition of atopy to atopic dermatitis 
(Table 1.3) (38).  
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Table 1.3 The ‘MOAHLFA’ index describes important demographic 
characteristics of patch testing populations. 
M Male gender 
O Occupational causation 
A Background of atopic dermatitis 
H Hand dermatitis 
L Leg ulcer or dermatitis 
F Facial dermatitis 
A Age > 40 years 
 
 On multivariate analysis the MOAHLFA characteristics were associated 
with rates of positivity to certain allergens (39). For example, age and gender 
were associated with sensitisation to cobalt, nickel and colophonium; hand 
eczema with nickel; and leg ulcer or eczema with colophonium. It is 
suggested that the MOAHLFA characteristics are reported alongside patch 
test results to help with the interpretation of findings (37). This is of particular 
interest when comparing results from different centres. After correcting for 
these known confounders, differences in sensitisation rates can be associated 
with the allergen exposure of the testing population, genetic susceptibility of 
the sample population and differences in patch testing methodology between 
sites. We would expect allergen exposure to vary with socioeconomic status 
due to differences in occupations and social behaviors, however the influence 
of social status on patch test results is scarcely described in the literature, 
with the exception of nickel allergy, which has been associated with smoking 
and unemployment (40, 41). 
 ACD occurs at all ages although sensitisation is less likely in early 
infancy. The risk of ACD in children increases with age and sensitisation to 
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certain allergens appear to be increasing, possibly due to use of personal 
care products, hair dye and cosmetics at an earlier age (42). A Danish study 
found approximately one third of children aged 1 to 17 years referred for patch 
testing had a final diagnosis of allergic contact dermatitis (43). Common 
sensitisers in children are shown in table 1.4. In older adults the risk of ACD is 
influenced by physiologic, immunologic and chronological factors such as 
impaired barrier function of aged skin and greater cumulative lifetime 
exposure to allergens in contrast with relatively impaired immunity and 
reduced numbers of resident Langerhans cells (44). Topical preparations 
such as neomycin, lanolin and parabens are commonly reported causes of 
ACD in the elderly, particularly those used in the management of leg ulcers 
(4). Other frequent sensitisers mirror those found in the general population 
including nickel and fragrances (45).  
 
Table 1.4 Examples of causes of allergic contact dermatitis in children.  
Allergen Exposure 
Poison ivy, oak and sumac Plants 
Rubber chemicals Shoes and gloves 
Potassium dichromate Leather shoes 
Nickel Jewellery, metal clothing and mobile 
phones 
Ethylenediamine 
hydrochloride 
Topical medications  
Cobalt chloride Jewellery and metal clothing 
Neomycin Topical antibiotic 
Fragrance Perfumes and cosmetics 
Myroxylon pereirae Perfumes and cosmetics 
Thiomersal Cosmetics, topical antiseptics, vaccines 
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Methylisothiazolinone Cosmetics and baby wipes 
p-Phenylenediamine (PPD) Hair dye and henna tattoos 
 
Contact dermatitis is the most common occupational skin disease, 
however, in the workplace, irritant reactions are more common than ACD. 
ACD may be due to exposure to specific workplace chemicals, but also due to 
common products such as preservative and fragrances in hand cleansers or 
rubber accelerators in gloves. Examples of other occupational exposures are 
shown in table 1.5. When planning patch testing, it is advisable to take a 
careful history of occupational exposures and utilise additional special series 
where relevant. An Australian study in Victoria found highest rates of 
occupational skin disease (including irritant and allergic contact dermatitis) in 
hairdressers, machine and plant operators and health care workers (46). Of 
note, methacrylates in artificial gel nails are an important, emerging 
occupational allergen for nail technicians (47). One report found rates of 
contact sensitisation decreased with increasing occupational training ranging 
from 45.9% in unskilled workers to 12.5% in those who had attended a school 
of engineering (48). 
Individuals with atopic dermatitis have ample exposure to potential 
allergens contained in topical products such as moisturisers and 
corticosteroids over the chronic course of their disease. For this group, a 
number of factors influence the risk of contact sensitisation, including impaired 
skin barrier function allowing enhanced penetration of haptens and the altered 
immune and bacteriological profile of the skin (49). Despite this, experimental 
studies have shown reduced rates of sensitisation to dinitrochlorobenzene in 
individuals with atopic dermatitis compared with controls (50). A potential 
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explanation is that T helper subtype 2 (Th2) cell activity in the skin in atopic 
dermatitis may antagonise the T helper 1 (Th1) response required for contact 
sensitisation (51).   
Hamann et al performed a meta-analysis of 74 published studies to 
assess the association of atopic dermatitis and contact sensitisation (52). 
Overall, they found no change in the risk of contact sensitisation for those with 
atopic dermatitis compared with the overall population (odds ratio 0.891, 95% 
confidence interval 0.771 to 1.03). However, on subgroup analysis those with 
atopic dermatitis were less likely to be sensitised than patients presenting for 
patch testing with other dermatoses (who did not have atopic dermatitis). 
Similar results were found in a systematic review of 31 studies in children; of 
those referred for patch testing 41.7% with atopic dermatitis were sensitised 
to at least one allergen compared with 46.6% of children without atopic 
dermatitis (odds ratio 0.85, 95% confidence interval 0.74-0.98 for children with 
atopic dermatitis) (53). For most studies in this systematic review the control 
group was children without atopic dermatitis presenting for patch testing (that 
is selected by their clinician as having a suspicion of contact allergy) who 
have a higher pretest probability than children in the general population. 
Considering this, the conclusion drawn from these studies is that patch testing 
should be considered for children and adults with atopic dermatitis, 
particularly in severe or recalcitrant cases, or cases where there is a sudden 
unexplained flaring or unusual distribution.  
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Table 1.5 Occupational causes of allergic contact dermatitis. Adapted from 
Fisher’s Contact dermatitis, chapter 24 (4). 
Occupation Example allergens 
Bakers Sorbic acid (flour preservative), flour flavours (e.g. 
cinnamon, cloves, garlic), karaya gum (pastry filler), 
benzoyl peroxide (flour bleacher), antioxidants and 
chromates in flour. Flour may cause contact urticaria.  
Construction workers Chromate (cement), cobalt, nickel, epoxy resin, 
rubber allergens. 
Dairy workers Rubber allergens, chlorhexidine (teat care), animal 
wool, dichromate as milk preservative.  
Dentists Gold, acrylates, rubber chemicals, nickel, fragrance. 
Gardeners Plants (e.g. Compositae family), pesticides. 
Hairdressers Hair dyes (e.g. PPD, toluenediamine), bleach 
(ammonium persulfate), rubber allergens (gloves), 
perm solution (glycerol thioglyconate), nickel, 
shampoo (e.g. cocamidopropyl betaine), fragrances. 
Healthcare workers Rubber allergens (gloves), colophonium, latex, 
fragrances, formaldehyde and other preservatives. 
Painters Fungicides and preservatives in paints (e.g. 
chloracetamide, methylisothiazolinone), acrylates, 
colophonium, dyes (e.g. cobalt chloride, potassium 
dichromate), paint thinners (e.g. turpentine). 
Photographers Developers (e.g. PPD), fixers (e.g. potassium alum); 
bleaches (e.g. potassium dichromate), toners (e.g. 
gold and platinum).  
Printers Pigments, acrylates, isocyanates, potassium 
dichromate, dyes, formaldehyde, glues.  
Textile workers Textile dyes, formaldehyde (textile finishers), rubber 
allergens. 
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Regional allergic contact dermatitis 
 Of the seven MOAHLFA criteria, three refer to regional contact 
dermatitis (hands, legs and face). In general, the first site to be involved in 
ACD represents the site of contact with the allergen. Over time the dermatitis 
may generalise or spread making a careful history of the rash at onset vital.  
 Dermatitis of the hands is a common presentation at the patch testing 
clinic and aetiology may be endogenous (atopic), irritant or allergic in nature. 
Psoriasis of the hands has clinicopathological overlap with hand dermatitis 
and should be considered in the differential diagnosis. Patch testing is 
required to diagnose ACD of the hands, as clinical presentation alone is 
unreliable. Relevant allergens include nickel, chromates, food allergens, 
fragrances, rubber allergens, PPD and topical preservatives (figure 1.5). 
Consumption of nickel in food can exacerbate pompholyx-type dermatitis in 
some individuals (54). 
 Contact sensitisation in patients with leg ulcers is common and 
increases with duration of disease (55). The common allergens are 
components of dressings or topical medicaments including fragrances, 
parabens, benzocaine, iodine, colophonium, lanolin and topical antibiotics 
(especially neomycin). Disruption of skin barrier function and the chronicity of 
disease with exposure to multiple topical products is likely to explain the 
increased risk of sensitisation in this subgroup. 
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Figure 1.5 Allergic contact dermatitis of the hands. This chef had a positive 
patch test reaction to dodecyl gallate on day 4. This allergen is found in butter 
and margarine handled daily by this patient when preparing pastry and pasta. 
 
  
 The face has several areas of interest when considering a diagnosis of 
ACD. For example, earlobe dermatitis is a classic sign of nickel allergy and 
perioral dermatitis may be due to cosmetics, food or toothpaste (56, 57). The 
eyelids are particularly sensitive and a number of allergens and irritants 
should be considered (see table 1.6). Eyelid dermatitis may occur due to 
transfer of allergens from a distant site and may be the only site of 
involvement. For example, nail polish reactions often involve the eyelids and 
neck with sparing of the paronychial area. In contrast with the eyelid area, the 
scalp is relatively resistant to ACD and allergens applied to the scalp often 
produce contact dermatitis elsewhere. 
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Although not included in the MOAHLFA index, contact dermatitis of the 
anogenital region is well described in the literature. In an Adelaide study, 
patch testing detected a relevant contact reaction in 44% of women with 
vulval pruritus (58). Contact allergy was more frequently seen in women with 
dermatitis on histopathology.  Frequent allergens include topical medications 
including anaesthetics), corticosteroids, preservatives and fragrances (59-61). 
Other notable allergens include methylisothiazolinone (MI) found in wet wipes 
and rubber in condoms leading to reactions in men and women (62, 63). 
Components of sanitary pads including colophonium (rosin) and 
methyldibromo glutaronitrile (a preservative) are reported to cause vulval 
allergic contact dermatitis in case reports from Australasia (64, 65). Irritant 
contact dermatitis is also frequently encountered in this group owing to the 
moist and occluded environment of genital skin (66). 
 
Table 1.6 Examples of causes of eyelid dermatitis. 
Endogenous 
dermatoses 
Atopic dermatitis 
Seborrhoeic dermatitis 
Psoriasis 
Exogenous 
dermatoses 
Irritant contact dermatitis 
e.g. eye cosmetics, sunscreen, solvents, soap emulsifiers 
Allergic contact dermatitis 
e.g. hair dye, cosmetics, nail polish, gel nails, nickel, 
preservatives in eye drops, hairspray, shampoo 
Airborne contact dermatitis 
e.g. insecticides, animal hairs, volatile chemicals, pollen, dust 
 
Due to an increased number of recent referrals we have been 
interested in contact allergy of the lips leading to cheilitis. In a North American 
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review of 10,061 patients with cheilitis undergoing patch testing more than 
one third had a final diagnosis of allergic contact dermatitis (67). Interestingly, 
cheilitis or perioral eczema may be the presenting feature of contact allergy to 
allergens primarily in contact with oral mucosal surfaces, for example 
toothpaste, and are not always accompanied by stomatitis (68). Other 
relevant allergens include components of lipsticks (such as gallates, waxes, 
colophonium, sunscreens and fragrances), dental components (such as 
acrylates and metals) and foods or flavourings (69-75).  
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Patch testing in Australia 
 
The Australian Baseline Series 
A baseline (or standard) series is a set of the most important and relevant 
allergens (or mixes of allergens) in the environment of a patch tested 
population. The majority of patients presenting with suspected ACD are tested 
to a baseline series, which can compensate with gaps in the clinical history 
ensuring relevant allergens are not missed. Amongst various baseline series 
used worldwide there are roughly 40 allergens in common (17). A comparison 
of baseline series allergens is shown in Appendix three. Although 
International baseline series exist, most centres utilise a regional specific 
series owing to differences in environmental allergens (occurring naturally or 
in industry) (76). As allergen use and exposure changes with time baseline 
series should be regularly updated to reflect this. It is proposed that a baseline 
series should include allergens positive in greater than 0.5-1% of a tested 
population although a considered and evidence-based approach should be 
employed as some allergens are of low relevance or alternatively, of particular 
interest (15). Adverse events such as irritant reactions, toxic or teratogenic 
effects and potential for inducing sensitisation should also be considered. 
 While the use of a baseline series in patch testing is widely accepted, 
studies have shown that when used alone they are unlikely to be sufficiently 
sensitive in detecting a sufficient proportion of relevant allergens. Patel and 
colleagues found when testing with 28 TRUE test® allergens only 27.6% of 
patients had all allergens identified (77). They suggested that, for adequate 
sensitivity, a baseline series should include allergens responsible for at least 
50% of ACD cases in a given location. 
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In Australia, patch test data has been published by the large occupational 
and contact dermatitis centre in Melbourne, Victoria. In 2015, this group 
published a review of their patch test results over a ten-year period as the 
basis for a new ‘Australian baseline series’ (ABS) (78). This paper included 
numbers of positive and relevant results for 5,281 patients tested between 
2001 and 2010. The most common allergens included fragrance mix I, nickel 
sulfate, potassium dichromate, Myroxylon pereirae (balsam of Peru), 
formaldehyde and PPD. Sixty allergens were selected to form the ABS based 
on the frequency of positive results. A brief description of ABS allergens is 
outlined in Appendix four. Selected allergens with lower rates of positivity 
were included if particular relevance was noted. For example, Basic red 46 
was included due to cases of foot dermatitis in Australia caused by its 
presence in acrylic-blend socks and chloroacetamide and was included as it is 
a sensitising preservative found in the widely used Redwin brand sorbolene in 
Australia (79, 80).  
 The number of allergens in the various baseline series ranges from 24 
(Japanese baseline series) to 70-80 (American Contact Dermatitis Society 
and Mayo Clinic Baseline Series). The European baseline series has 30 
allergens. The ABS has a relatively large number of allergens and increasing 
the number of allergens in a baseline series is shown to increase sensitivity 
(77). There are advantages to having a large baseline series, particularly in a 
geographically vast country such as Australia, where patients often live in 
rural areas without access to large tertiary patch testing centres. A historical 
study from the same clinic in Melbourne showed that patch testing with a 
standard series of 37 allergens resulted in full detection of relevant allergens 
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in only 42% and 19% had none of their relevant reactions detected by the 
standard series (81). A larger baseline series reduces the need for additional 
specialised series and assists clinicians without broad experience in contact 
allergy to perform a meaningful assessment. Indeed, there are many cases 
where the culprit allergen is only evident after a positive patch test result 
provokes a more directed history (even for the most experienced clinicians) 
(82).  
An alternate viewpoint is that a larger baseline series results in 
increased cost in testing irrelevant allergens and less physical space on the 
patients’ skin for relevant additional series or testing to the patient’s own 
products. The current baseline series’ used at NSW testing sites in 
Darlinghurst and Westmead, which have approximately 30 allergens and are 
almost invariably supplemented as above. 
 
Patch test data from New South Wales 
 There is little published literature on allergic contact dermatitis in the 
population of NSW. Rosen and Freeman published a series from the 
Occupational Dermatology clinic at the Skin and Cancer Foundation in 
Darlinghurst (now named the Skin Hospital) in 1992 (83). Five hundred and 
seventy patients were reviewed over a six-year period of which 38.2% had 
ACD. The most common allergens were potassium dichromate (18.3%), 
thiuram (17%), epoxy resins (17%), nickel sulfate (12.4%) and cobalt chloride 
(10.1%). Allergen frequencies varied between men and women and 25% of 
women had a positive reaction to nickel. While this paper gives us some 
insight into ACD in NSW, this population was selected for an occupational 
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skin disease clinic and had different demographics to the usual patch test 
population in that the majority (56.1%) were men and young to middle-aged 
adults (range 15 to 75 years). Subsequently, these results are not 
generalisable to the broader population. Given the scarcity of local data, the 
relevance of the ABS in NSW patients is unknown. Assessing the 
performance of the ABS in our population has the potential to change clinical 
practice and subsequently reduce costs and wasted resources. 
Overview of following chapters 
 Little has been documented about the characteristics of patients 
presenting for patch testing in NSW. The first section of this thesis describes 
the population presenting for patch testing at the Skin Hospitals in 
Darlinghurst and Westmead and presents allergen frequencies with regard to 
demographic factors. Later sections investigate geographic differences in 
allergen frequencies, both within the state and interstate. This information has 
the potential to inform patient-specific allergen selection and enhance validity 
of patch testing in NSW patients. The final section of this thesis describes the 
presentation of patients with regional ACD involving the lips and anogenital 
area in our NSW cohort. 
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2. Methods 
Study design and population 
This was a retrospective observational study of patients completing 
patch testing at The Skin Hospitals in Darlinghurst and Westmead in NSW. 
Data was collected from 1/01/2002 to 31/12/2016 and this cohort is described 
as the “total-population”. Given contact allergens change with time, and to 
describe results with current relevance, a more recent cohort tested from 
1/01/2007 to 31/12/2016 was used for most analyses and is described as the 
“last-ten-years”. For analyses of some sub-groups (e.g. review of reactions to 
hairdressing allergens) the total-population was used to provide adequate 
numbers. 
All patients completing testing (including children) with results entered 
into the Microsoft Access database at each site during the study period were 
included. Patients were referred to The Skin Hospitals for patch testing by 
general practitioners, dermatologists or other specialists. Clinics were 
supervised by a dermatologist with expertise in patch testing.  Patch testing 
methodology is outlined in the literature review chapter of this thesis. First 
readings were done on day two and final readings were undertaken on day 
four or seven. Results of patch testing were documented according to the 
International Contact Dermatitis Research Group grading system. 
Interpretation of relevance according to the supervising dermatologist was 
recorded as “Relevant, Old or Unknown”. This data, including patient 
demographics, clinical history and results had been entered into the database 
on completion of testing. 
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As we were accessing identifiable personal health information ethics 
approval was sought and granted from The University of Sydney Human 
Research Ethics committee. 
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Variables collected from database 
 
Main variables 
• Testing site (Darlinghurst or Westmead) 
• Pre and post-patch test diagnoses 
• Tested series, own products 
• Positive reactions (defined as a +, ++ or +++ result on the final reading) 
• Relevant positive results (as recorded by the supervising dermatologist 
on the final reading) 
 
Confounding variables 
• Supervising consultant  
• Patient demographics (age at time of testing, sex, occupation) 
• Atopic dermatitis background 
• Site of dermatitis 
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Data analysis 
 
Data was extracted from the Microsoft Access database to Excel for 
initial analysis. Data were randomly checked against the clinical record for 
accuracy. Patient identifiers were removed and data was stored in The 
University of Sydney eNotebooks.  
Statistical analyses and graphs were done with SPSS Statistics version 
23 (IBM software). Variables are described in terms of mean (with standard 
deviation) if approximately normally distributed and median (with interquartile 
range) if there was a skewed distribution. Proportions of positive allergens for 
different groups were compared using chi-squared test (or Fisher’s exact test 
if counts were less than five). Comparison of mean values between groups 
was calculated with a two-sample t test. Multivariate analysis was performed 
for patients with and without cheilitis using binary logistic regression with co-
variables identified as confounders (age, gender, atopic dermatitis, history of 
any atopy). The significance level was set at α=0.05.  
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3. Demographics and Allergens 
Patient baseline characteristics 
Objectives 
To describe the baseline demographic and clinical characteristics of 
patients presenting for patch testing at The Skin Hospitals in NSW. 
 
Results 
There were 3,460 patients patch tested from 1/01/2002 to 31/12/2016 
(total-population) and 1,584 patients tested from 1/01/2007 to 31/12/2016 
(last-ten-years). In the last-ten-years there were 579 patients patch tested at 
the Darlinghurst site and 1,005 at Westmead. The mean age of patients 
tested was 43.6 years (standard deviation [SD] 17.6; range 2 to 93). The ages 
of patients tested were similar for men and women, mean 43.8 and 43.5 
respectively (see figure 3.1). Almost two thirds of patients tested were women 
and more women were tested across all age groups (see figure 3.2). Age and 
gender characteristics were similar between the two testing sites (see table 
3.1). Overall, a greater proportion of patients were tested at Westmead than 
Darlinghurst and in the last five years patient data from the Darlinghurst site 
was reduced (see figure 3.3). 
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Figure 3.1 Age at time of patch testing for men and women. Graph shows 
mean (central line) and interquartile range (ends of rectangle). 
 
 
Figure 3.2 Age ranges of patients undergoing patch testing by gender. 
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Table 3.1 Characteristics of patients undergoing patch testing at the Skin 
Hospitals, New South Wales in the last-ten-years. 
Characteristic Frequency (%) 
Male 531 (33.5) 
Age > 40 years 877 (55.4) 
Children ≤ 16 years 84 (5.3) 
Older adults ≥ 65 203 (12.8) 
Occupational cause 115 (7.3) 
Atopic dermatitis 343 (21.7) 
Any atopy 515 (32.5) 
Hand dermatitis 252 (15.9) 
Leg ulcer or dermatitis 119 (7.5) 
Facial dermatitis 370 (23.4) 
 
Figure 3.3 Numbers of patients undergoing patch testing at sites in 
Darlinghurst (DH) and Westmead (WM) in the last-ten-years. 
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Discussion 
The last-ten-years cohort was selected for the majority of analyses as 
this is the cohort of current relevance (given known trends and changes in 
ACD over time). This time period provided 1,584 patients, which we felt to be 
an adequate sample size to examine patient demographics and the 
MOAHLFA characteristics.  
The mean age of patients tested was 43.6 years compared with a 
mean age of 40.0 years in the large study from Victoria that was the basis for 
the ABS (78). Similar to our study, the Victorian study found roughly half of 
their population had an age above 40 years, which is considered an important 
demographic criterion in patch test data reporting. The Skin Hospitals in 
Darlinghurst and Westmead accept referrals for adults and children and 
approximately 5% of the population tested were children aged 16 years or 
less. The Victorian study does not specify if children were tested; 40% of the 
patients in this study were from an occupational dermatology clinic and would 
exclude children. In keeping with this, a relatively high proportion of 
occupational cases and hand dermatitis were included in the Victorian study 
(26% and 36%, respectively compared with 7% and 16% in our study and 9% 
and 20% in a large North American report (84)). Rates of dermatitis affecting 
the face and legs and the proportion of patients with atopic dermatitis were 
comparable between sites. 
Consistent with the Victorian and other reports we found more women 
presented for patch testing than men. Epidemiologic studies suggest that 
contact sensitisation is more common in women (34) and this is thought to be 
secondary to gender differences in allergen exposure rather than genetic 
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susceptibility to sensitisation (85). For example, exposure to perfume and 
jewellery leads to more allergies to fragrances and nickel in women (86, 87). 
Another potential reason for seeing more women in the patch test clinic 
relates to differences in health behaviour between the sexes. Men are 
generally less likely than women to seek help from healthcare professionals 
(88). 
Overall, fewer patients were recorded at Darlinghurst than Westmead 
and the number of patients tested at Darlinghurst in the last-five-years was 
less than half of the previous five-year period. Potential reasons for this 
include changes in staffing and database entry practice. Data is entered at the 
Westmead site by a patch test nurse specialist (who has a long service 
provision history), however in recent times data entry at the Darlinghurst site 
is by the registrar allocated to the clinic. Because registrars change regularly, 
and training/orientation is required for the Microsoft Access database it is 
more difficult to ensure data entry is consistent. If data entry were the reason 
however, there is no reason to believe that inconsistencies would lead to 
differential bias as patient’s allocation to clinics with different registrars is 
mostly random. Low patient numbers reduces our confidence in drawing 
conclusions from the Darlinghurst cohort when viewed in isolation and is 
acknowledged as a weakness of this study and data analysis to follow. 
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Allergen positivity rates 
Objectives 
 To describe outcomes of patch testing for patients at The Skin 
Hospitals in NSW and to describe the effect of age and gender on patch test 
results. 
 
Results 
Comprehensive results of testing for all allergens in the last-ten-years 
are shown in appendix five and the most common allergens are shown in 
table 3.2. These were nickel sulfate (n=119), cobalt chloride (n=59), 
Myroxylon pereirae (n=58), fragrance mix I (n=55), PPD (n=41) and 
potassium dichromate (n=39). Positive reactions to patients own products 
were seen in 162 cases (10.2%). Four hundred and forty-one patients had at 
least one reaction (27.8%) and the mean number of reactions was 0.7 (SD 
1.4).  
Rates of positivity and relevance to gallates were higher than expected 
and to investigate this the records of patients having a relevant positive 
reaction to dodecyl or octyl gallate were subsequently reviewed. In the total-
population (1/01/2002 to 31/12/2016) there were 24 relevant reactions to 
gallates (see table 3.3). Causes of ACD to gallates included eyelid cosmetics, 
handling of cooking oils and margarine and ingestion of foods. Clinical 
presentations included hand dermatitis, eyelid dermatitis, cheilitis and 
stomatitis. 
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Table 3.2 Allergens positive in at least 0.5% of patients tested in the last-ten-
years (n=1584). 
Allergen Positive       
(% total) 
Relevant     
(% total) 
Relevant/ 
positive (%) 
Nickel sulfate 119 (7.6) 18 (1.1) 15.1 
Cobalt chloride 59 (3.7) 7 (0.4) 11.9 
Myroxylon pereirae 58 (3.7) 16 (1.0) 27.6 
Fragrance mix I 55 (3.5) 21 (1.3) 38.2 
p-Phenylenediamine 41 (2.6) 28 (1.8) 68.3 
Potassium dichromate 39 (2.5) 8 (0.5) 20.5 
MCI/MI 31 (2.0) 20 (1.3) 64.5 
Dodecyl gallate 31 (2.0) 11 (0.7) 35.5 
Colophonium 27 (1.7) 9 (0.6) 33.3 
Thiuram mix 22 (1.4) 12 (0.8) 54.5 
Methylisothiazolinone 21 (1.3) 16 (1.0) 76.2 
Thiomersal 21 (1.3) 1 (0.1) 4.8 
Quaternium 15 17 (1.1) 7 (0.4) 41.2 
Carba mix 15 (0.9) 4 (0.3) 26.7 
Methyldibromo glutaronitrile 14 (0.9) 5 (0.3) 35.7 
Sodium metabisulfite 14 (0.9) 1 (0.1) 7.1 
Formaldehyde 12 (0.8) 5 (0.3) 41.7 
2,5-Diamtoluene sulfate 11 (0.7) 8 (0.5) 72.7 
Toluenesulfonamide formadehyde 
resin 
11 (0.7) 5 (0.3) 45.5 
Ammonium persulfate 10 (0.6) 7 (0.4) 70.0 
Tea tree oil 10 (0.6) 6 (0.4) 60.0 
Epoxy resin 10 (0.6) 2 (0.1) 20.0 
Cinnamic alcohol 9 (0.6) 7 (0.4) 77.8 
Octyl gallate 9 (0.6) 0 (0.0) 0.0 
Parabens mix 8 (0.5) 5 (0.3) 62.5 
Chloroacetamide 8 (0.5) 0 (0.0) 0.0 
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Table 3.3 Relevant positive reactions to gallates in the total-population (n=24). 
Gallate Presentation Source of gallate 
Dodecyl gallate 
(n=19) 
Octyl gallate (n=5) 
Cheilitis (n=6) 
Facial dermatitis (n=6) 
Hand dermatitis (n=4) 
Eyelid dermatitis (n=3) 
Stomatitis (n=2) 
Generalised dermatitis 
(n=1) 
Missing data (n=2) 
Foods (n=8) 
Eye makeup (n=5) 
Cooking oils and 
margarine (n=5) 
Unknown (n=5) 
  
The mean number of reactions was highest in those aged 40-64 years. 
The positivity rate for children aged 16 years or less was 20.3% compared 
with 30.5% for adults aged over 16 years (p=0.053). Number of reactions by 
age group is shown in table 3.4. 
 
Table 3.4 Total number of positive patch test reactions by age group in the 
last-ten-years. 
Age in 
years 
Number of positive reactions (% within age group) 
0 1 2 3 4-6 7-9 10+ Total  
≤ 16 67 
(79.8) 
7 (8.3) 4 (4.8) 4 (4.8) 1 (1.2) 1 (1.2) 0 (0.0) 84 
17-39 381 
(68.8) 
71 (12.8) 50 (9.0) 30 (5.4) 20 (3.6) 0 (0.0) 2 (0.4) 554 
40-64 477 
(68.2) 
90 (12.9) 51 (7.3) 30 (4.3) 44 (6.3) 4 (0.6) 3 (0.4) 699 
≥ 65 150 
(73.9) 
15 (7.4) 17 (8.4) 15 (7.4) 5 (2.5) 1 (0.5) 0 (0.0) 203 
Total 1075 
(69.8) 
183 (11.9) 122 (7.9) 79 (5.1) 70  (4.5) 6 (0.4) 5 (0.3) 1540 
*44 cases with missing data excluded 
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There were 84 children aged 16 years or less tested in the last-ten-
years. The most frequent allergens in children were nickel sulfate, potassium 
dichromate, cobalt chloride, fragrance mix I, 
Methylchloroisothiazolinone/methylisothiazolinone (MCI/MI), Basic red 46 and 
thiomersal. Table 3.5 shows positive patch results in children. 
 
Table 3.5 Positive patch test reactions in children aged 16 years or less in the 
last-ten-years. 
Allergen Positive 
reactions 
% 
(n=84) 
Nickel sulfate 6 7.1 
Potassium dichromate 2 2.4 
Cobalt chloride 2 2.4 
Fragrance mix I 2 2.4 
MCI/MI 2 2.4 
Basic red 46 2 2.4 
Thiomersal 2 2.4 
Myroxylon pereirae 1 1.2 
Colophonium 1 1.2 
p-Phenylenediamine 1 1.2 
Quaternium 15 1 1.2 
Budesonide 1 1.2 
Cocamide DEA 1 1.2 
Benzophenone 4 1 1.2 
Hydroxyisohexyl 3-cyclohexene carboxaldehyde 1 1.2 
25-Diaminotoluene sulfate 1 1.2 
Desonide 0.5mg/g 1 1.2 
Paratertiarybutyl phenol formaldehyde 1 1.2 
Sodium metabisulfite 1 1.2 
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There were 203 older adults aged 65 years or older patch tested over 
the last-ten-years. Fifty-two of these had at least one positive reaction. 
Fragrances were the most common allergens in this group accounting for a 
total of 19/113 positive reactions. Patch test reactions in older adults are 
shown in table 3.6. 
 
Table 3.6 Positive patch test reactions in adults aged 65 years or more in the 
last-ten-years. 
Allergen Positive reactions % (n=203) 
Myroxylon pereirae 10 4.9 
Potassium dichromate 8 3.9 
Dodecyl gallate 7 3.4 
Nickel sulfate 5 2.5 
4-Phenylenediamine 5 2.5 
Cobalt chloride 5 2.5 
Fragrance mix I  4 2.0 
Colophonium 3 1.5 
Neomycin sulfate 3 1.5 
MCI/MI 3 1.5 
Quaternium 15 3 1.5 
Benzocaine 3 1.5 
Methyldibromo Glutaronitrile 3 1.5 
Oxybenzone (Eusolex 4360) 3 1.5 
Diazolidinyl urea 2 1.0 
Formaldehyde 2 1.0 
Epoxy resin 2 1.0 
Toluenesulfonamide formaldehyde resin 2 1.0 
Tea tree oil 2 1.0 
Geraniol 2 1.0 
Octyl gallate 2 1.0 
Sodium metabisulfite 2 1.0 
Lanolin  1 0.5 
Imidazolidinyl urea 1 0.5 
Thiuram mix 1 0.5 
Mercapto mix 1 0.5 
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Allergen Positive reactions % (n=203) 
4-tert-Butylphenol formaldehyde resin 1 0.5 
Propylene glycol 1 0.5 
Cetearyl alcohol 1 0.5 
Chlorocresol 1 0.5 
Basic red 46 1 0.5 
Methylprednisolone aceponate 1 0.5 
Carba Mix 1 0.5 
Benzophenone 3 1 0.5 
Benzalkonium chloride  1 0.5 
Disperse blue 106 1 0.5 
Disperse blue mix (124/106) 1 0.5 
2-Bromo-2-nitropropane-1,3-diol 1 0.5 
Methylisothiazolinone 1 0.5 
135-Tris(2-hydroxyethyl)hexahydrotriazine 1 0.5 
25-Diaminotoluene sulfate 1 0.5 
2-Nitro-4-phenylenediamine 1 0.5 
4-Aminoazobenzene 1 0.5 
4-Aminophenol 1 0.5 
Cinnamic aldehyde 1 0.5 
Epoxy acrylate 1 0.5 
Ethylenediamine dihydrochloride 1 0.5 
Glutaraldehyde 1 0.5 
Isoeugenol 1 0.5 
Melamine formaldehyde (Kaurit M70) 1 0.5 
N-Methylol chloroacetamide  0.1% 1 0.5 
Oakmoss absolute 1 0.5 
Paratertiarybutyl phenol formaldehyde 1 0.5 
Urea formaldehyde (Kaurit S) 1 0.5 
 
We found very strong evidence that the rates of positivity for PPD and 
nickel sulfate varied with age. The highest rates of positivity to PPD were 
seen in adults aged 40 to 64 years followed by older adults aged 65 years or 
more. The lowest rates were seen in young adults and children (p=0.001). 
Rates of nickel positivity were highest in young adults aged 17-39 years and 
lowest in adults aged 65 years or more (p=0.001). 
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Table 3.7 Percentage of patients testing positive in the last-ten-years by age 
(allergens tested in >95% of the population). 
  Age when tested (years) Chi-square or 
Fisher's exact test <= 16 17- 39 40 - 64 65+ 
n=84 n=554 n=699 n=203 p-value 
PPD 1.19% 0.72% 4.43% 2.46% 0.001 
Carba Mix 0.00% 1.08% 1.14% 0.49% 0.922 
Cobalt chloride 2.38% 5.05% 3.43% 2.46% 0.304 
Colophonium 1.19% 1.81% 1.86% 1.48% 1.000 
Quaternium 15 1.19% 1.08% 1.00% 1.48% 0.856 
Epoxy resin 0.00% 0.36% 0.86% 0.99% 0.658 
Ethylenediamine 
dihydrochloride 
0.00% 0.18% 0.14% 0.49% 0.599 
Methyldibromo 
Glutaronitrile 
0.00% 0.54% 1.14% 1.48% 0.517 
Formaldehyde 0.00% 1.26% 0.43% 0.99% 0.345 
Fragrance mix I 2.38% 2.71% 4.72% 1.97% 0.148 
Imidazolidinyl urea 0.00% 0.18% 0.57% 0.49% 0.657 
Mercapto mix 0.00% 0.36% 0.57% 0.49% 0.920 
Neomycin sulfate 0.00% 0.18% 0.43% 1.48% 0.150 
Nickel sulfate 7.14% 11.01% 6.44% 2.46% 0.001 
Parabens mix 0.00% 0.54% 0.29% 0.00% 0.773 
Potassium 
dichromate 
2.38% 2.35% 2.29% 3.94% 0.594 
Thiuram mix 0.00% 1.62% 1.72% 0.49% 0.522 
Toluenesulfonamide 
formaldehyde resin 
0.00% 0.18% 1.14% 0.99% 0.170 
Lanolin 0.00% 0.18% 0.57% 0.49% 0.657 
 
There was evidence that more women tested positive for nickel sulfate 
and cobalt chloride compared with men (see table 3.8). No other differences 
in allergen positivity were seen between the genders. 
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Table 3.8 Positive results in the last-ten-years for standard series allergens by 
gender. 
 Allergen Gender Chi-square or 
Fisher's exact Male % 
positive 
Female % 
positive 
(n=531) (n=1028) p-value 
p-Phenylenediamine 1.51% 3.11% 0.057 
4-tert-butylphenol formaldehyde resin 0.19% 0.29% 1.000 
Baslam of Peru 4.52% 3.31% 0.231 
Benxyl alcohol 0.00% 0.00% 1.000 
Benzocaine 0.38% 0.39% 1.000 
Black rubber mix 0.00% 0.00% 1.000 
Budesonide 0.19% 0.29% 1.000 
Carba Mix 1.51% 0.68% 0.113 
Chlorocresol 0.19% 0.00% 0.341 
Cobalt chloride 2.45% 4.47% 0.047 
Colophonium 1.51% 1.85% 0.624 
Diazolidinyl urea 0.38% 0.49% 1.000 
Disperse blue mix (124/106) 1.13% 0.00% 0.002 
Epoxy acrylate 0.38% 0.10% 1.000 
Epoxy resin 0.94% 0.49% 0.323 
Ethylenediamine dihydrochloride 0.00% 0.29% 0.555 
Formaldehyde 0.38% 0.97% 0.358 
Fragrance mix I 2.82% 3.89% 0.280 
Imidazolidinyl urea 0.56% 0.29% 0.416 
MCI/MI 1.69% 2.04% 0.636 
Mercapto mix 0.56% 0.39% 0.696 
Mercaptobenzothiazole 0.38% 0.19% 0.609 
Methyldibromo Glutaronitrile 0.75% 0.97% 0.783 
Methylisothiazolinone 0.38% 1.85% 0.017 
N-isopropyl-N-phenyl-4-phenylenediamine 0.19% 0.19% 1.000 
Neomycin sulfate 0.38% 0.39% 1.000 
Nickel sulfate 3.39% 9.63% <0.001 
Parabens mix 0.38% 0.29% 1.000 
Potassium dichromate 2.64% 2.43% 0.806 
Propylene glycol 0.00% 0.19% 0.551 
Quaternium 15 1.13% 1.07% 0.914 
Sesquiterpene lactone mix 0.19% 0.00% 0.341 
Tea tree oil 0.38% 0.78% 0.509 
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 Allergen Gender Chi-square or 
Fisher's exact Male % 
positive 
Female % 
positive 
(n=531) (n=1028) p-value 
Thiuram mix 2.07% 1.07% 0.112 
Tixocortol-21pivalate 0.00% 0.00% 1.000 
Toluenesulfonamide formaldehyde resin 0.19% 0.97% 0.111 
Lanolin 0.38% 0.39% 1.000 
Discussion  
Our top allergens are not unexpected and are amongst some of the 
most common allergens worldwide. Compared with the most recent North 
American Contact Dermatitis Group results, nickel, fragrance mix I, cobalt 
chloride, Myroxylon pereirae and MCI/MI were shared top ten allergens (84). 
The European Surveillance System on Contact Allergies (ESSCA) collated 
results from 11,643 patch-tested patients. Top allergens were very similar to 
ours; nickel, fragrance mix, Myroxylon pereirae, cobalt chloride, potassium 
dichromate, PPD, colophonium, thiuram mix, methyldibromo glutaronitrile and 
MCI/MI (89). Comparison with published patch test data from Victoria is 
discussed in the next chapter. 
Dodecyl gallate seems to be an outlier. It was the eighth most common 
allergen in our cohort despite not being on the baseline series at either of The 
Skin Hospital’s testing sites and more than a third of reactions were 
considered relevant. Dodecyl gallate is often not included in baseline series 
(including the NACDG and ESSCA screening series) due to historically low 
documented relevance rates. Dodecyl, octyl and propyl gallate are 
antioxidants used as preservatives in food and cosmetics. They are often 
found in fatty foods such as oil and margarine and are moderate to strong 
sensitisers (90). Gallate use in cosmetics has increased over the last few 
decades and rates of ACD to gallates are increasing (91). A recent systematic 
review published in 2017 found 74 reported cases of ACD to gallates from 
1975 to 2014 (92). Eyelid and lip cosmetics were responsible for most cases 
and propyl gallate was the most common allergen accounting for 63% of 
cases. However, a retrospective review from Victoria found, that of 29 
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relevant or possibly relevant reactions to gallates, 16 were to dodecyl gallate 
(93). Sources included cooking oils, margarine and lip cosmetics. The authors 
comment that determining relevance can be difficult due to inadequate 
product labeling. 
In our patients, dodecyl gallate was also the most common gallate to 
test positively and the most common exposures were foods and eyelid 
cosmetics. Toholka et al found 7% of patients in Victoria tested positively to 
dodecyl gallate, however relevance was low (78). Similar to our findings, 
reactions to octyl and propyl gallate were less common. It is possible that 
allergy to dodecyl gallate is disproportionate in Australia compared to globally 
and this may warrant further investigation. 
In the last-ten-years, 28% of patients had at least one positive reaction. 
This figure is low compared to North America (67%) and Victorian data (78%), 
however these rates are on the higher end of the spectrum (78, 84). The 
proportion of patients with at least one positive reaction is known as the 
“positivity rate” and provides useful information when interpreting reports of 
patch testing for a given population. Uter and colleagues found significant 
variation in the positivity rate among 53 European departments ranging from 
25 to 70% (with one outlying department at 91%). It has been suggested that 
a “P” for positivity rate could be added to the MOAHLFA index to form 
“MOAHLFAP” (94) and that for patch testing to be cost effective the positivity 
rate should lie between 30 and 65%.(95)  
Factors influencing the positivity rate include how strictly patients are 
selected for patch testing (this influences the pre-test probability), the number 
of allergens tested as well as the background level of sensitisation in the 
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patch-tested population. A lower rate such as ours suggests selection of 
patients for testing is less restrictive (which is logical given The Skin Hospitals 
are private clinics and accept referrals from general practitioners). 
Unfortunately, we did not have data available for descriptive analysis on the 
numbers of allergens tested per patient at our clinics. Limited data from the 
NSW population in the past makes it difficult to comment on potential contact 
sensitisation rates in NSW, however it would be unexpected for rates to differ 
so dramatically with Victoria. Another explanation for our low positivity rate is 
a problem with data entry (positive results not being recorded on the database 
when testing is completed). The previous section of this thesis highlighted 
potential data entry problems at the Darlinghurst site. In this data set most, 
but not all allergens were more commonly positive at Westmead, suggesting 
data entry does not fully account for this disparity.  
We saw the highest number of reactions in adults aged 40 to 64 years 
and there was weak evidence that the positivity rate was higher for adults 
compared with children. The literature is conflicting on this. Wohrl et al found 
highest rates in children with a small second peak at 30 years (96) whereas 
Goh found higher rates in adults compared with children (97). Reported 
positivity rates in children vary widely (27-65%) (42, 98). Numbers of children 
patch tested in our study were low; the analysis may not have adequate 
power to detect a small, true difference in the positivity rate between children 
and adults (type II error). 
The most common allergens in children were similar to the adult 
population with the addition of Basic red 46 and thiomersal appearing in the 
top ten. In a review of 1,142 children (aged up to 18 years) from the United 
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States the top allergens were nickel, fragrance mix I, cobalt dichloride, 
Myroxylon pereirae, neomycin sulfate, propylene glycol, cocamidopropyl 
betaine, bacitracin, fomaldehyde and gold (98). A positive reaction to 
thiomersal was seen in 3.1% of children. Basic red 46 was not reported, 
however this study was collated from clinics using various baseline series 
including TRUE test® which do not include Basic red 46. Thiomersal is a 
preservative found in cosmetics, contact lens solutions and vaccines. It is 
commonly among the top allergens seen in children (99), however relevance 
is usually historical and because of this thiomersal is not often included in 
baseline series.  
Allergens in older adults were similar to the general population which is 
a common finding (100). Myroxylon pereirae (a fragrance) was the most 
common allergen in this group. When compared with children and other 
adults, Wantke et al found reaction to Myroxylon pereirae was more common 
in the elderly, likely due to cumulative lifetime exposure to products containing 
fragrance and increased use of topical medicaments (which contain 
fragrance) in older adults (101). 
Consistent with the literature, rates of nickel sensitisaion varied with 
age and were highest in children and young adults (102, 103). Landeck and 
colleagues suggest this may reflect social trends such as increased rates 
body piercing in young adults (102). The rise in popularity of cellphones may 
be another influence. Up to one third of cellphones contain nickel and there 
have been numerous reports of ACD secondary to nickel content in 
cellphones in both children and adults over the last decade (104, 105).  
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PPD positivity was highest in middle-aged and older adults. There was 
also weak evidence that PPD allergy was more common in women. Most 
cases of PPD allergy are secondary to dark shade hair dye although cases 
secondary to black henna tattoos are becoming more prevalent and 
sensitisation by henna exposure may lead to more severe reactions (106, 
107). In the study by Landek et al PPD did not feature in the top ten allergens 
for patients aged 20-39 years but was the 4th most common allergen in those 
aged 40-59 years and 5th for those aged 60 years or over (102). A Spanish 
study found exposure patterns in patients with PPD allergy varied with age 
(108). Three subgroups were found; the youngest group sensitised by henna 
(mean age15 years), the middle group was hairdressers with occupational 
hair dye exposure (mean age 35 years) and the oldest group was consumer 
hair dye users (mean age 46 years). Our data included one child (aged 9 
years) with positivity to PPD who was sensitised by a henna tattoo. This child 
also had a cross reaction to 2,5 diamtoluene sulfate.  
The overall rate of sensitisation to PPD in our cohort was 3% 
compared with approximately 4% in Europe, 7% in North America and 5% in 
another Australian study (78, 84, 109). Regional variation in PPD allergy 
occurs, for example Thyssen and colleagues found highest prevalence in 
regions expected to have more dark-haired individuals such as North 
America, Asia and non-Scandinavian European countries (110). This likely 
reflects darker shade PPD-containing hair dye use to mask greying hair. 
Australian census data show the most common ancestries in NSW in 2016 
were English (23%), Australian (23%), Irish (8%), Scottish (6%) and Chinese 
(5%) and this was almost identical to Victoria (111). These ethnic similarities 
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mean the disparity in PPD sensitisation seen between the states is more likely 
secondary to either social differences in hair dye use or different selection 
criteria between the two patch test clinics. This is supported by the overall 
lower positivity rate of our data compared with Taholka and coleagues. 
Allergy to nickel and cobalt were more common in women likely 
reflecting exposure differences to metals in men and women. Cobalt is found 
as an impurity in many nickel products and co-sensitisation to nickel, cobalt 
and chromate is commonly seen (112). Nickel allergy is strongly associated 
with ear piercing (113). A population-based study from Germany found 
women were more likely to be sensitised than men to both nickel and cobalt, 
with odds ratios of 4.15 (95% CI 2.74-6.33) and 2.57 (95%CI 1.06-6.40), 
respectively (48).  
In summary, analysis of allergen positivity rates allowed comparison of 
data with available literature and established the integrity of our dataset. 
Notable findings were a relatively low positivity rate, high rates of positivity 
and relevance to dodecyl gallate and expected demographic associations for 
sensitisation to thiomersal, Myroxylon pereirae, PPD, nickel sulfate and cobalt 
chloride. 
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Trends in patch test results 
Objectives 
 To assess differences in the positivity rates for standard series 
allergens over the last-ten-years. 
 
Results 
Given the small amount of data from the Darlinghurst site in the last-5-
years (see figure 3.3), trends by time were examined within the Westmead 
cohort only. Between 1st January 2007 and 31st December 2011 there were 
522 patients tested at Westmead and between 1st January 2012 and 31st 
December 2016 there were 482 patients tested. Baseline characteristics of 
patients tested by time period are shown in table 3.9. There were less 
occupational cases seen in the more recent five-year period (p<0.001) and a 
higher proportion of patients aged greater than 40 years in this time period.  
The mean age of patients tested from 2007 to 2011 was 41 years (SD 18.3) 
compared with 45 years (SD 17.1) in the period from 2012 to 2016 (p<0.001). 
We found very strong evidence that rates of positivity to nickel sulfate 
and MCI/MI have increased in the most recent time period. Nickel increased 
from 6.3% to 13.1% (p<0.001) and MCI/MI from 1.0% to 4.8% (p<0.001). 
There was strong evidence positive testing to cobalt chloride and potassium 
dichromate has increased in the last 5 years (6.9% and 5.4% in the period 
2012-2016 compared with 3.1% and 1.5% in the period 2007 to 2011, 
p=0.005, p=0.001 respectively). Positive testing to PPD, Myroxylon pereirae, 
colophonium and benzocaine has also increased (see table 3.9). 
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Table 3.9. Baseline characteristics of patients undergoing patch testing at the 
Skin Hospital in Westmead by time period. 
Characteristic 2007 to 2011 
n=522 (%) 
2012 to 2016 
n=482 (%) 
Chi-square or 
Fisher’s exact p-
value 
Male 170 (32.6) 158 (32.8) 1.000 
Age >40 years 268 (51.3) 286 (59.3) 0.009 
Occupational cause 74 (14.2) 30 (6.2) <0.001 
Atopic dermatitis 139 (26.6) 116 (24.1) 0.351 
Any atopy 223 (42.7) 191 (39.6) 0.320 
Hand dermatitis 115 (22.0) 101 (21.0) 0.678 
Leg ulcer or dermatitis 57 (10.9) 43 (8.9) 0.291 
Facial dermatitis 158 (30.5) 159 (33.0) 0.354 
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Table 3.10 Results of patch testing to standard series allergens at the Skin 
Hospital in Westmead by time period. 
 Allergen Period Chi-square or 
Fisher's exact 
p-value 
Positive 
2007 to 2011 
n=523 
Positive 
2012 to 2016 
n=482 
p-Phenylenediamine 1.91% 4.77% 0.011 
4-tert-butylphenol formaldehyde resin 0.19% 0.62% 0.355 
Myroxylon pereirae 3.63% 7.26% 0.011 
Benzocaine 0.00% 1.04% 0.025 
Carba Mix 0.96% 1.45% 0.469 
Chlorocresol 0.00% 0.21% 0.480 
Cobalt chloride 3.06% 6.85% 0.005 
Colophonium 1.15% 3.11% 0.030 
Epoxy acrylate 0.57% 0.00% 0.251 
Epoxy resin 0.38% 1.04% 0.270 
Ethylenediamine dihydrochloride 0.57% 0.00% 0.251 
Formaldehyde 0.57% 1.24% 0.325 
Fragrance mix I 5.16% 4.77% 0.776 
Imidazolidinyl urea 0.38% 0.41% 1.00 
MCI/MI 0.96% 4.77% <0.001 
Mercapto mix 0.19% 0.83% 0.200 
Mercaptobenzothiazole 0.19% 0.62% 0.355 
Methyldibromo Glutaronitrile 0.96% 0.62% 0.727 
N-isopropyl-N-phenyl-4-phenylenediamine 0.19% 0.41% 0.610 
Neomycin sulfate 0.57% 0.21% 0.626 
Nickel sulfate 6.31% 13.07% <0.001 
Parabens mix 0.00% 0.41% 0.230 
Potassium dichromate 1.53% 5.39% 0.001 
Quaternium 15 1.34% 1.04% 0.661 
Thiuram mix 1.15% 2.28% 0.163 
Toluenesulfonamide formaldehyde resin 0.38% 0.83% 0.435 
Lanolin  0.57% 0.21% 0.626 
Methylisothiazolinone * 3.32% - 
*Methylisothiazolinone not tested on standard series prior to 2012 
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Discussion 
Increased sensitisation rates were seen to metals (nickel, cobalt and 
potassium dichromate), MCI/MI, PPD, colophonium, Myroxylon pereirae and 
benzocaine in the last five years. Due to a time lag in publication of patch test 
data from large groups in Europe and the United States, data for comparison 
from literature for this time period is limited. 
Metal sensitivity in Europe has shown a downwards trend after the 
introduction of the European Union Nickel Directive in 2001 and similar results 
were seen after Danish nickel regulation introduced in 1990 (114, 115). These 
regulations stated consumer products should release less than 0.5μg of 
nickel/cm2/week, which was further reduced to a maximum of 0.2μg/cm2/week 
in 2004. They were later updated to include cellphones after the epidemic of 
cellphone dermatitis cases previously discussed (116). There is no such 
regulation in Australia, which may explain the increase seen.  
Chromate is found in metals, cement, yellow-green pigments and 
leather. While chromate allergy has traditionally presented with hand 
dermatitis in construction workers with occupational exposure to cement, 
exposure to leather shoes and clothing is now the most common exposure 
source and may explain increasing rates in young women (117). A Swedish 
study found increased rates of sensitisation to chromate in young women, 
despite a reduction for nickel in this group, with a rate of 5.4% in women in 
2009 (118). In contrast a large German study found a decrease in chromate 
sensitivity from 6% in 2007 to 3% in 2012 (119). The authors attribute this to 
reduced chromate content in cement. Of note, this study had a higher 
proportion of older adults compared with ours (73% greater than 40 years 
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compared with 55% in our cohort). Interestingly, we found similar rates of 
chromate sensitisation in men and women. Australia does not have legislation 
to reduce available chromate in cement which may account for differences 
between our data and reports from Europe (120). 
MCI/MI is a preservative initially primarily used in industry and MI was 
introduced as a stand-alone preservative in consumer products in 2005 with a 
permitted concentration of 100 ppm (more than 26-fold the previous limit) 
(121). Since that time there has been a worldwide epidemic of contat allergy 
to MI and patch testing to MI alone, in addition to MCI/MI, is now standard as 
testing MCI/MI alone may miss up to half of cases (123, 124). Patch testing to 
MI alone was introduced at The Skin Hospitals in NSW in 2012 and therefore 
was only tested in the later part of our cohort influencing our overall reported 
sensitisation rate. Chow and colleagues reported causes of preservative 
allergy from 1993-2006 in patients from NSW and Victoria (122). This study 
found a positivity rate of 2% to MCI/MI. Our data showed sensitisation to 
MCI/MI in 5% and to MI in 3% the last 5 years, however if we consider not all 
patients were tested to MI in this time period these rates are likely to 
underestimate MI sensitisation.  
Fall and colleagues reported patch-testing trends in Sweden from 1992 
to 2009 (118). As this study captures an earlier time period to ours, and was 
published just prior to the MI epidemic, they found a decrease in sensitisation 
rates to MCI/MI. However, similar to our findings they documented a rise in 
PPD sensitisation from 1.4% in 1992 to 2.1% in 2009 and attributed this to 
increasing use of hair dyes. As discussed previously, black henna tattoos are 
also an important recent source of PPD sensitisation in children and young 
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adults. This study found sensitisation to Myroxylon pereirae was stable and 
sensitisation to fragrance mix I was decreasing. We found increasing rates of 
sensitisation to Myroxylon pereirae and colophonium (which can be a marker 
of fragrance allergy). Further studies from Europe have also demonstrated 
decreasing rates of fragrance sensitisation (125, 126) however the NACDG 
found positivity rates to fragrance mix I and cinnamic aldehyde (another 
fragrance) had increased in 2011/2012 (127). These differences likely reflect 
local product manufacturing, availability and consumer use.  
 A limitation of this analysis is that reported data is from one site only, 
reducing patient numbers. Further, as there are only two time periods 
compared, results need to be confirmed with ongoing data collection. 
In conclusion, the trends identified raise the need for further research, 
including confirmation of increasing nickel sensitisation, which is converse to 
some International reports, through ongoing data collection and comparison 
with other Australian centres. The increase in chromate sensitisation may 
reflect a shift in the demographics of chromate allergy given our young, and 
predominantly female, patient cohort and further study of the clinical 
presentation of chromate allergy in recent times is warranted.  
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4. Comparison of NSW testing sites 
Comparison of results from Darlinghurst and Westmead 
 
Objectives 
 To assess for differences in allergen positivity rates between to two 
NSW testing sites (Darlinghurst and Westmead). 
 
Results 
Baseline characteristics of patients tested at The Skin Hospitals in 
Darlinghurst and Westmead in the last-ten-years are shown in table 4.1. 
Allergens positive in at least 0.5% of patients tested at either site are shown in 
table 4.2. After multivariate analysis adjusting for differences in MOAHLFA 
characteristics, the following allergens were more frequently positive at the 
Westmead site; Myroxylon pereirae (p<0.001), fragrance mix I (p=0.003), 
nickel sulfate (p=0.013), MCI/MI (p=0.026), sorbitan sesquioleate (p=0.038), 
potassium dichromate (p=0.039) and PPD (p=0.044). More patients at the 
Darlinghurst site tested positively for dodecyl gallate (p<0.001) and disperse 
blue mix (p=0.018). 
Using Bonferroni correction for multiple comparisons the significant p 
value was <0.001 for 71 comparisons. Using this correction there was only 
evidence for a difference between sites in positivity for Myroxylon pereirae 
and Dodecyl gallate. 
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Table 4.1 Comparison of baseline characteristics of patients undergoing patch 
testing at the Skin Hospitals in Darlinghurst and Westmead in the last-ten-
years. 
Characteristic Darlinghurst 
n=579 (%) 
Westmead   
n=1005 (%) 
Chi-square or 
Fisher’s exact 
p-value 
Male 202 (34.9) 329 (32.7) 0.382 
Age > 40 years 322 (55.6) 555 (55.2) 0.881 
Children ≤ 16 years 23 (4.0) 61 (6.1) 0.073 
Older adults ≥ 65 71 (12.3) 132 (13.1) 0.617 
Occupational cause 11 (1.9) 104 (10.3) <0.001 
Atopic dermatitis 87 (15.0) 256 (25.5) <0.001 
Any atopy 100 (17.3) 515 (32.5) <0.001 
Hand dermatitis 35 (6.0) 217 (21.6) <0.001 
Leg ulcer or dermatitis 19 (3.3) 100 (10.0) <0.001 
Facial dermatitis 53 (9.2) 317 (31.5) <0.001 
 
Table 4.2 Comparison of patch test results at Darlinghurst and Westmead 
from in the last-ten-years for allergens positive in ≥0.5% at either site. Logistic 
regression adjusted for occupational causation, site of dermatitis and atopy. 
 
Allergen 
Darlinghurst 
n=579 
% positive 
Westmead 
n=1005 
% positive 
Multivariate 
analysis  
p value 
Methylisothiazolinone 0.9 1.6 0.364 
Mercury 0.2 0.2 0.580 
Basic red 46 0.9 0.1 0.052 
Nickel sulfate 4.0 9.6 0.013 
Dodecyl gallate  3.5 1.1 <0.001 
Disperse blue 106 0.5 0.1 0.206 
Ammonium persulfate 0.2 0.9 0.289 
2-Nitro-4-phenylenediamine 0.2 0.3 0.823 
Tea tree oil 1.7 0.0 0.988 
Cobalt chloride 1.7 4.9 0.115 
Cinnamic alcohol 0.3 0.7 0.689 
Cinnamic aldehyde 0.3 0.3 0.335 
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Allergen 
Darlinghurst 
n=579 
% positive 
Westmead 
n=1005 
% positive 
Multivariate 
analysis  
p value 
p-Phenylenediamine 1.4 3.3 0.044 
Amerchol L 101 0.2 0.0 0.990 
Sodium metabisulfite   0.2 1.3 0.139 
Methyldibromo glutaronitrile 1.0 0.8 0.290 
Octyl gallate   0.9 0.4 0.085 
P-tert-butylphenol formaldehyde resin 1.0 0.4 0.987 
Colophonium 1.0 2.1 0.441 
Benzophenone 3 0.2 0.9 0.429 
Disperse Red 1 0.2 0.1 0.477 
4-Aminophenol 0.2 0.3 0.992 
Disperse blue mix (124/106) 0.9 0.1 0.018 
Fragrance mix I 0.9 5.0 0.003 
Potassium dichromate 0.9 3.4 0.039 
Quaternium 15 0.9 1.2 0.881 
Parabens mix 0.9 0.3 0.187 
Thiuram mix 0.9 1.7 0.577 
Toluenesulfonamide formaldehyde resin 0.9 0.6 0.435 
Cocamidopropyl betaine 0.5 0.1 0.231 
Diazolidinyl Urea 0.5 0.4 0.170 
Myroxylon pereirae 0.7 5.4 <0.001 
Budesonide 0.7 0.0 0.987 
DMDM Hydantoin 0.3 0.0 0.989 
Sorbitan sesquioleate 0.3 0.1 0.038 
MCI/MI 0.5 2.8 0.026 
Epoxy resin 0.5 0.7 0.847 
Carba Mix 0.5 1.2 0.563 
Formaldehyde 0.5 0.9 0.976 
Neomycin sulfate 0.5 0.4 0.215 
2,5-Diaminotoluene sulfate 0.0 1.1 0.992 
Palladium Chloride 0.0 0.4 0.992 
Glutaraldehyde  0.0 0.4 0.993 
Glyceryl monothioglycolate 0.0 0.4 0.991 
Melamine formaldehyde 0.0 0.3 0.992 
Thiomersal  0.0 2.1 0.992 
Copper sulfate 0.0 0.3 0.991 
4-Aminoazobenzene 0.0 0.4 0.992 
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Allergen 
Darlinghurst 
n=579 
% positive 
Westmead 
n=1005 
% positive 
Multivariate 
analysis  
p value 
Urea formaldehyde  0.0 0.2 0.991 
Benzophenone 4 0.0 0.3 0.992 
Disperse orange 3 0.0 0.3 0.992 
Potassium dicyanoaurate 0.0 0.2 0.992 
2 Hydroxyethyl methacrylate 0.0 0.4 0.992 
Geraniol 0.0 0.6 0.992 
Isoeugenol 0.0 0.6 0.992 
Desonide 0.0 0.2 0.990 
Methylprednisolone aceponate 0.0 0.2 0.992 
Limonene 0.0 0.5 0.992 
3-Aminophenol 0.0 0.3 0.992 
Coconut diethanolamide 0.0 0.7 0.992 
Chloroacetamide 0.0 0.8 0.992 
Ethyleneglycol dimethacrylate  0.0 0.2 0.992 
Methyl methacrylate  0.0 0.2 0.992 
Benzalkonium chloride 0.0 0.6 0.992 
Sodium benzoate 0.0 0.5 0.992 
N-Methylol chloroacetamide 0.0 0.5 0.992 
Peppermint oil 0.0 0.2 0.992 
Eugenol 0.0 0.2 0.992 
Cetearyl alcohol 0.0 0.3 0.993 
Benzocaine 0.2 0.5 0.154 
Mercapto mix 0.3 0.5 0.879 
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Discussion 
Basic demographics of gender and age distribution were similar 
between the two sites. However, there was evidence of differences in other 
MOAHLFA characteristics including occupational causation, atopy and site of 
involvement and these indices were adjusted for on multivariate analysis. All 
were all less commonly recorded at the Darlinghurst site and this may 
represent (at least in part) the suspected problems with data recording at this 
site described on page 47 of this thesis.  
There was strong evidence that fragrance sensitisation was more 
common at the Westmead site. There were higher rates of facial dermatitis 
and Westmead; a common manifestation of fragrance allergy. Around one-
third of patients with sensitivity to fragrance mix I presented with facial 
dermatitis in a large Denmark study (128). However, after adjusting for the 
site of dermatitis on multivariate analysis, the trend towards increased 
fragrance sensitivity at Westmead remained. Further, Myroxylon pereirae (a 
marker of fragrance allergy) was also more frequently positive at this site, 
strengthening the likelihood that this is a true association. Possible 
explanations include differences in occupations and cultural variations 
between the regions. There are also socioeconomic differences. According to 
the 2016 Census the median weekly household income in Darlinghurst is 
$2,158 compared with $1,866 in Westmead (111). Although patients are 
referred from many regions it would be expected that they would be 
preferentially referred to the testing centre closest to their domicile. Therefore, 
it is reasonable to suspect the Darlinghurst patient cohort may be of a higher 
socioeconomic status than the Westmead cohort. 
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Dodecyl gallate was more frequently positive at the Darlinghurst site. 
Epidemiology and clinical aspects on gallate allergy have been discussed in 
the ‘Demographics and Allergens’ chapter of this thesis. If we look at just the 
patients tested to dodecyl gallate (n=1182, see Appendix 5) rather than the 
population as a whole the rate of positivity at Darlinghurst was 3.8% with 2.1% 
having a relevant reaction and at Westmead 1.7% were positive and none of 
these were considered relevant. A possible explanation for this result is a 
discrepancy in practice between physicians at the two sites with perhaps an 
overestimate of positivity and relevance in Darlinghurst. However, on 
reviewing cases of ACD to gallates, relevance and the source of the gallate 
was well documented (see table 3.3). Another possible reason would be a 
difference in gallate exposure between the two sites such as different food 
consumption habits or cosmetic product choice, although this seems unlikely. 
Finally, the differences in final reading times between the sites may have 
some impact. Readings were conducted at day two and four at Westmead, 
however in Darlinghurst a proportion of final readings were done on day 
seven. This means allergens known to be ‘late reactors’ may have been 
detected more readily at the Darlinghurst site. Interestingly, in a retrospective 
study of 36,064 patch test readings from the Mayo clinic dodecyl gallate was 
one of the top four late reactors (25).  
Positivity to metals (nickel and potassium dichromate) may be higher at 
the Westmead testing site than Darlinghurst although this effect was lost after 
the Bonferroni correction. Established demographic and social factors 
associated with nickel allergy are female gender, younger age, hand 
dermatitis, absence of atopy, cigarette smoking, shorter length of higher 
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education and possibly lower socioeconomic status or income (40, 129). A 
study from Germany found higher rates of nickel sensitisation in nurses and 
receptionists (25-29%) compared with physicians (12%) (130).  Nickel is 
known to be a late reactor and therefore the difference between the two sites 
may have been even greater if the readings were done on the same schedule 
consistently. Therefore, for this allergen the timing of readings does not 
appear to be an important limiting factor. The timing of the final reading may 
have also influenced fragrance reactions, which may fade after day 5 (25) and 
therefore could be underestimated in the Darlinghurst group, a further 
explanation for the trend to reduced fragrance sensitisation compared with 
Westmead. 
In summary, key findings include increased sensitivity to fragrance and 
possibly metals at Westmead, which may be related to socioeconomic factors 
and warrants further investigation; greater sensitisation to dodecyl gallate at 
Darlinghurst, which may be related to delayed day seven readings performed 
for patients at this site. Comparison between the two sites was limited by 
possible data entry omissions in Darlinghurst.  
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5. Comparison with Victoria and the 
Australian Baseline Series 
Performance of the Australian Baseline Series 
Objectives 
 To assess the positivity rates for Australian Baseline Series (ABS) 
allergens in the NSW population and assess the number of patients 
completely and partially diagnosed using ABS allergens. 
 
Results 
Data from patch testing to baseline series allergens in the ABS and 
local standard series from the Skin Hospitals in Westmead and Darlinghurst 
over the last 15 years (total-population) are presented in table 1. Eleven of 
these allergens were positive in less than 0.5% of patients tested and nine of 
these are ABS allergens; chlorocresol, benzyl alcohol, tixocortol-21-pivalate, 
propylene glycol, triamcinolone acetonide, betamethasone valerate, 
iodopropyl butylcarbamate, cetearyl alcohol and mixed dialkyl thiourea. The 
remaining two allergens were epoxy acrylate and primin, which are allergens 
on the standard series used at Westmead.  
Ethylenediamine dihydrochloride and N-isopropyl-N-phenyl-4-
phenylenediamine are on the standard series at Westmead and not included 
in the ABS. They were positive in 0.8% and 0.5% of patients tested, 
respectively. However, rates of relevant positives to these allergens were low.  
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There were 68 reactions to the non-baseline series hairdressing 
allergens 2,5- diamtoluene sulfate and ammonium persulfate in the total-
population. Of these, 35 had no occupation recorded. The most common 
occupations for the remaining 33 were hairdresser (n=20), office manager 
(n=4), beauty therapist (n=2), Sales (n=2), student (n=2), pharmacist (n=1), 
housewife (n=1) and receptionist (n=1). 
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Table 5.1 Results of patch testing to allergens in the Australian Baseline Series (ABS) and local standard series in Darlinghurst and Westmead, New South 
Wales from 1 January 2002 to 31 December 2016. Descending order by percentage positive from tested in the combined patient cohort from both sites. 
Allergen ABS no. 
Darlinghurst (n=1463) Westmead (n=1997) Total (n=3460) 
Tested Rel  Rel % tested Pos 
Pos % 
tested Tested Rel  
Rel % 
tested Pos  
Pos % 
tested Tested Rel 
Rel % 
tested Pos  
Pos % 
tested 
Pos % 
total 
Nickel sulfate 2 1442 29 2.0 142 9.8 1958 55 2.8 310 15.8 3400 84 2.5 452 13.3 13.1 
Methylisothiazolinone 60 33 3 9.1 3 9.1 122 13 10.7 16 13.1 155 16 10.3 19 12.3 0.5 
Cobalt chloride 10 1442 17 1.2 62 4.3 1958 28 1.4 193 9.9 3400 45 1.3 255 7.5 7.4 
Fragrance mix I 1 1442 17 1.2 43 3.0 1958 87 4.4 174 8.9 3400 104 3.1 217 6.4 6.3 
Balsam peru 4 1442 12 0.8 33 2.3 1959 65 3.3 179 9.1 3401 77 2.3 212 6.2 6.1 
Bufexamac 53 0 0 0.0 0 0.0 35 2 5.7 2 5.7 35 2 5.7 2 5.7 0.1 
Potassium dichromate 3 1434 16 1.1 38 2.6 1958 30 1.5 114 5.8 3392 46 1.4 152 4.5 4.4 
p-Phenylenediamine  6 1293 19 1.5 31 2.4 1960 44 2.2 78 4.0 2598 63 2.4 109 4.2 3.2 
2-hydroxyethyl methacrylate 27 2 0 0.0 0 0.0 285 6 2.1 12 4.2 287 6 2.1 12 4.2 0.3 
Benzophenone 4 33 137 1 0.7 1 0.7 319 8 2.5 18 5.6 456 9 2.0 19 4.2 0.5 
Benzophenone 3 30 81 1 1.2 2 2.5 318 4 1.3 13 4.1 399 5 1.3 15 3.8 0.4 
Fragrance mix II  39 33 1 3.0 1 3.0 0 0 0.0 0 0.0 33 1 3.0 1 3.0 0.0 
Colophonium 8 1442 14 1.0 41 2.8 1959 28 1.4 62 3.2 3401 42 1.2 103 3.0 3.0 
Lidocaine 50 36 1 2.8 1 2.8 106 1 0.9 3 2.8 142 2 1.4 4 2.8 0.1 
Thiuram mix 7 1443 17 1.2 29 2.0 1959 24 1.2 48 2.5 3402 41 1.2 77 2.3 2.2 
Benzalkonium chloride 49 56 0 0.0 0 0.0 1378 5 0.4 32 2.3 1434 5 0.3 32 2.2 0.9 
Quaternium 15 9 1442 11 0.8 22 1.5 1960 22 1.1 49 2.5 3403 33 1.0 71 2.1 2.1 
Formaldehyde 5 1442 10 0.7 18 1.2 1958 15 0.8 51 2.6 3400 25 0.7 69 2.0 2.0 
MCI/MI 11 1434 10 0.7 19 1.3 1912 33 1.7 51 2.7 3346 43 1.3 67 2.0 1.9 
Disperse blue mix 124/106 36 1251 5 0.4 12 1.0 315 12 3.8 18 5.7 1566 17 1.1 30 1.9 0.9 
Basic red 46 17 273 7 2.6 8 2.9 329 3 0.9 3 0.9 602 10 1.7 11 1.8 0.3 
Tea tree oil 21 1011 6 0.6 18 1.8 0 0 0.0 0 0.0 1011 6 0.6 18 1.8 0.5 
Cocaminopropyl betaine 23 672 4 0.6 7 1.0 1193 9 0.8 24 2.0 1865 13 0.7 31 1.7 0.9 
Chloroacetamide 28 184 0 0.0 0 0.0 1405 9 0.6 25 1.8 1589 9 0.6 25 1.6 0.7 
Lyral 24 162 5 3.1 5 3.1 477 3 0.6 5 1.0 639 8 1.3 10 1.6 0.3 
Methylprednisolone 
aceponate cream  42 377 6 1.6 7 1.9 390 2 0.5 5 1.3 767 8 1.0 12 1.6 0.3 
Carba Mix 44 1442 6 0.4 13 0.9 1907 8 0.4 38 2.0 3349 14 0.4 51 1.5 1.5 
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Allergen ABS no. 
Darlinghurst (n=1463) Westmead (n=1997) Total (n=3460) 
Tested Rel  Rel % tested Pos 
Pos % 
tested Tested Rel  
Rel % 
tested Pos  
Pos % 
tested Tested Rel 
Rel % 
tested Pos  
Pos % 
tested 
Pos % 
total 
Diazolidinyl Urea  12 649 4 0.6 6 0.9 1200 13 1.1 18 1.5 1849 17 0.9 24 1.3 0.7 
Amerchol L 101 22 81 1 1.2 1 1.2 0 0 0.0 0 0.0 81 1 1.2 1 1.2 0.0 
Compositae mix 15 397 4 1.0 5 1.3 13 0 0.0 0 0.0 410 4 1.0 5 1.2 0.1 
4-tert-butylphenol 
formaldehyde resin 29 1435 12 0.8 23 1.6 1959 4 0.2 18 0.9 3394 16 0.5 41 1.2 1.2 
Neomycin sulfate 47 1442 0 0.0 16 1.1 1958 4 0.2 25 1.3 3400 4 0.1 41 1.2 1.2 
Epoxy resin  13 1440 6 0.4 16 1.1 1958 9 0.5 24 1.2 3398 15 0.4 40 1.2 1.2 
Coconut diethanolamide 20 995 4 0.4 4 0.4 1194 10 0.8 21 1.8 2189 14 0.6 25 1.1 0.7 
Imidazolidinyl urea 18 1442 4 0.3 15 1.0 1963 12 0.6 21 1.1 3405 16 0.5 36 1.1 1.0 
Benzocaine 48 1237 2 0.2 12 1.0 1958 3 0.2 20 1.0 3195 5 0.2 32 1.0 0.9 
Toluenesulfonamide 
formaldehyde resin  16 1442 8 0.6 14 1.0 1959 6 0.3 16 0.8 3401 14 0.4 30 0.9 0.9 
2-ethylhexyl-4-
methoxycinnamate 56 137 0 0.0 0 0.0 318 3 0.9 4 1.3 455 3 0.7 4 0.9 0.1 
Limonene 38 270 0 0.0 0 0.0 528 3 0.6 7 1.3 798 3 0.4 7 0.9 0.2 
Ethylenediamine 
dihydrochloride - 1393 2 0.1 9 0.6 1958 3 0.2 18 0.9 3351 5 0.1 27 0.8 0.8 
Parabens mix 45 1442 7 0.5 11 0.8 1961 4 0.2 14 0.7 3403 11 0.3 25 0.7 0.7 
Budesonide 46 1437 3 0.2 10 0.7 391 0 0.0 3 0.8 1828 3 0.2 13 0.7 0.4 
DMDM hydantoin 14 449 2 0.4 3 0.7 0 0 0.0 0 0.0 449 2 0.4 3 0.7 0.1 
4-chloro-3,5-xylenol 52 6 0 0.0 0 0.0 1376 2 0.1 9 0.7 1382 2 0.1 9 0.7 0.3 
2-bromo-2-nitropropane-
1,2-diol 51 524 2 0.4 3 0.6 1378 4 0.3 9 0.7 1902 6 0.3 12 0.6 0.3 
Betamethasone 
dipropionate  58 277 0 0.0 0 0.0 528 0 0.0 5 0.9 805 0 0.0 5 0.6 0.1 
Lanolin (wool alcohols) 19 1442 2 0.1 8 0.6 1958 5 0.3 13 0.7 3400 7 0.2 21 0.6 0.6 
Sesquiterpene lactone mix 26 1433 1 0.1 8 0.6 94 1 1.1 1 1.1 1527 2 0.1 9 0.6 0.3 
Mercapto mix 32 1443 7 0.5 9 0.6 1959 5 0.3 11 0.6 3402 12 0.4 20 0.6 0.6 
Mercaptobenzothiazole 31 1436 4 0.3 7 0.5 1960 6 0.3 12 0.6 3396 10 0.3 19 0.6 0.5 
Black rubber mix 41 1434 3 0.2 8 0.6 0 0 0.0 0 0.0 1434 3 0.2 8 0.6 0.2 
N-Isopropyl-N-phenyl-4-
phenylenediamine - 147 0 0.0 1 0.7 1958 4 0.2 10 0.5 2105 4 0.2 11 0.5 0.3 
Chlorocresol   37 1434 7 0.5 8 0.6 1963 3 0.2 7 0.4 3397 10 0.3 15 0.4 0.4 
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Allergen ABS no. 
Darlinghurst (n=1463) Westmead (n=1997) Total (n=3460) 
Tested Rel  Rel % tested Pos 
Pos % 
tested Tested Rel  
Rel % 
tested Pos  
Pos % 
tested Tested Rel 
Rel % 
tested Pos  
Pos % 
tested 
Pos % 
total 
Benzyl alcohol 54 1124 0 0.0 1 0.1 1377 7 0.5 10 0.7 2501 7 0.3 11 0.4 0.3 
Tixocortol-21-pivalate 43 1437 2 0.1 5 0.3 392 0 0.0 2 0.5 1829 2 0.1 7 0.4 0.2 
Propylene glycol 34 1207 3 0.2 3 0.2 1194 1 0.1 5 0.4 2401 4 0.2 8 0.3 0.2 
Triamcinolone acetonide 57 302 1 0.3 1 0.3 0 0 0.0 0 0.0 302 1 0.3 1 0.3 0.0 
Epoxy acrylate - 8 0 0.0 0 0.0 1893 0 0.0 4 0.2 1901 0 0.0 4 0.2 0.1 
Betamethasone valerate 55 329 1 0.3 1 0.3 381 0 0.0 0 0.0 710 1 0.1 1 0.1 0.0 
Primin - 466 0 0.0 1 0.2 1958 0 0.0 2 0.1 2424 0 0.0 3 0.1 0.1 
Iodopropynyl 
butylcarbamate 59 954 0 0.0 1 0.1 0 0 0.0 0 0.0 954 0 0.0 1 0.1 0.0 
Cetearyl alcohol 35 498 0 0.0 0 0.0 0 0 0.0 0 0.0 498 0 0.0 0 0.0 0.0 
Mixed dialkyl thiourea 40 351 0 0.0 0 0.0 0 0 0.0 0 0.0 351 0 0.0 0 0.0 0.0 
Rel = relevant; Pos = positive; Blue = allergens tested on ABS and standard series at both Darlinghurst and Westmead; Yellow = tested on ABS and 
Darlinghurst standard series / not at Westmead; Green = Westmead standard series only / not tested on ABS or Darlinghurst standard series; Red = ABS 
allergens not tested on standard series at Darlinghurst or Westmead but may be included on other series. Allergens listed by percentage of patients tested 
with a positive reaction on the final reading. 
 
 
  
 Examinating the more recent cohort, 441 patients had at least one 
positive reaction in the last-ten-years. Two hundred and fifty-eight (58.5%) 
had all positive reactions detected by the ABS, 127 (28.8%) were partially 
evaluated (i.e. had at least one allergen detected but not all) and 56 (12.7%) 
had no allergens detected by the ABS.  
Overall, the ABS detected 71.5% of all positive reactions (see table 
5.2) and 72.9% of all relevant positive reactions. Table 5.3 shows allergens 
that are not included in the ABS and were positive 0.5% or more of the 
population. Table 5.4 shows ABS allergens positive in less the 0.5% of our 
cohort. 
 
Table 5.2 Number of positive reactions to allergens in the Australian Baseline 
Series (ABS) in the last-ten-years. 
Group Total positive 
reactions 
ABS reactions  
(% of total) 
Children ≤ 16 years (n=84) 30 24 (80.0) 
Older adults ≥ 65 years (n=203) 113 77 (68.1) 
All patients (n=1584) 941 673 (71.5) 
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Table 5.3 Non-Australian Baseline Series allergens positive in 0.5% or more 
of the population tested in the last-ten-years. 
Allergen Number of 
positives 
% Total 
population 
Dodecyl gallate 31 2.0 
Thiomersal 21 1.3 
Methyldibromo glutaronitrile 14 0.9 
Sodium metabisulfate 13 0.8 
2,5-Diaminotoluene sulfate 11 0.7 
Ammonium persulfate  10 0.6 
Cinnamic alcohol 9 0.6 
Octyl gallate 9 0.6 
Oakmoss absolute 8 0.5 
 
Table 5.4 Australian Baseline series allergens positive in less than 0.5% of 
the population tested in the last-ten-years. 
Allergen Number of 
positives 
% Total 
population 
Diazolidinyl urea 7 0.4 
Neomycin sulfate 7 0.4 
Mercapto mix 7 0.4 
Coconut diethanolamide 7 0.4 
Lanolin  6 0.4 
Imidazolidinyl urea 6 0.4 
Benzocaine 6 0.4 
Basic red 46 6 0.4 
Benzalkonium chloride  6 0.4 
Parabens mix 5 0.3 
Limonene 5 0.3 
2-Mercaptobenzothiazole 4 0.3 
Cocamidopropyl betaine 4 0.3 
Budesonide 4 0.3 
Benzophenone 3 4 0.3 
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Allergen Number of 
positives 
% Total 
population 
Hydroxyisohexyl 3-cyclohexene 
carboxaldehyde (Lyral) 
4 0.3 
Chloroxylenol 4 0.3 
2-Hydroxyethyl methacrylate 4 0.3 
4-tert-Butylphenol formaldehyde resin  3 0.2 
Cetearyl alcohol 3 0.2 
Benzophenone 4 3 0.2 
2-Bromo-2-nitropropane-1,3-diol 3 0.2 
Propylene glycol 2 0.1 
Methylprednisolone aceponate 2 0.1 
DMDM hydantoin 2 0.1 
Sesquiterpene lactone mix 1 0.1 
Chlorocresol 1 0.1 
Amerchol L 101 1 0.1 
Lidocaine 1 0.1 
Hydroperoxides of linalool NT NT 
Fragrance mix II 0 0.0 
Tixocortol-21-pivalate 0 0.0 
Benzyl alcohol 0 0.0 
Compositae mix 0 0.0 
Mixed dialkyl thiourea  0 0.0 
Betamethasone dipropionate 0 0.0 
Bufexamac 0 0.0 
Ethylhexyl methoxycinnamate 0 0.0 
Betamethasone valerate 0 0.0 
Triamcinolone acetonide 0 0.0 
Idodpropynyl butylcarbamate 0 0.0 
NT not tested; fragrance mix II only tested at Darllnghurst site 
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Discussion 
The ABS performed very well in detecting positive and relevant positive 
reactions, identifying nearly three quarters of relevant allergens (causes of 
ACD). Historically, a baseline series was thought to identify 70-80% of 
allergens (15) however varying figures are found in the literature. A North 
American report found 50% of positive reactions were to baseline series 
allergens (series size: 20 allergens) (131). Patel and Belsito found, using a 
screening series of 28 allergens, 27.6% had all allergens identified, 49.9% 
has some but not all allergens identified and 22.5% had no allergens detected 
(77). 
Testing with a larger number of allergens has been shown to increase 
detection of positive and relevant reactions and testing with a standard series 
alone (even a large series such as the ABS) is seldom adequate (132). Our 
findings agree with this; the ABS did not detect all positive or relevant positive 
reactions and supplementation with special series relevant to the individual 
clinical scenario was required. With this in mind, a practical concern with a 
larger baseline series, is finding the physical space to apply the allergens on 
the body. This is particularly pertinent for children, who not only have less 
surface area for applying patches but also are likely to be less compliant with 
patches applied on mobile areas such as limbs. A number of baseline series 
allergens are also unlikely to be relevant for children e.g. epoxy resin. Many 
centres have a modified baseline series designed for patch-testing children 
and the ABS was not designed for use in children.   
The German Contact Dermatitis Research Group has suggested a 
limited baseline series (12 allergens) for children 12 years and under, based 
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on surveillance studies in this population (133). Given our study included just 
38 children aged 12 and under it is difficult to utilise our data for the same 
process, however, it is recommended that contact sensitisation in children is 
monitored, so that less relevant allergens can be omitted and a paediatric 
ABS can be established. 
Several ABS allergens are not included in the local baseline series at 
Darlinghurst or Westmead (highlighted red in table 5.1). Of these a number 
were positive in >0.5% of the total-population. It could be argued that these 
allergens have a place on a baseline series in our population, however, 
patients tested to these allergens are likely to have been selected specifically 
for suspected relevance (rather than sequential baseline series-type testing) 
and so these results need to be interpreted carefully. For example, bufexamac 
(a topical anti-inflammatory) was positive in 5.7% of patients tested, but only 
0.1% of all patients presenting for patch testing during that period. This 
calculation is limited by the assumption that patients not tested would have 
had a negative result. 
ABS allergens iodopropyl butylcarbamate, cetearyl alcohol and mixed 
dialkyl thiourea were positive in <0.1% of the total-population. Iodopropyl 
butylcarbamate is a preservative found in personal care products. It is 
included on the ABS as well as the North American series (50 allergens), 
Portuguese Baseline Series (32 allergens) and the International 
Comprehensive Baseline Series (80 allergens). Toholka and colleagues found 
28 (0.7%) positive and 3 (0.07%) relevant reactions in 4,258 patients tested in 
Victoria (78). This low relevance rate, together with our data suggests 
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iodopropyl butylcarbamate may be a questionable inclusion on the ABS and 
could be more suited to inclusion on a specialised cosmetic series. 
Cetearyl alcohol is a weak sensitizer used as an emulsifier and 
emollient used in cosmetics and toiletries. It was a more common sensitiser in 
the Vicotrian study with 1.3% of patients testing positive and 0.3% having a 
relevant positive reaction (78). In addition to the ABS it is included on the 
British Standard series (41 allergens). Mixed dialkyl thiourea is a component 
of neoprene rubber positive in 0.9% and relevant in 0.3% of patients tested in 
the Victorian study (78). It is included on the North American series, 
International Comprehensive Baseline series, Latin American Baseline series, 
Chinese Baseline series and ABS. Further monitoring of reactions to cetearyl 
alcohol and mixed dialkyl thiorea in the Australian population is warranted to 
support ongoing inclusion on the ABS. 
Several allergens were positive in >0.5% of patch-tested patients in the 
last-ten-years which are not on the ABS. For some of these the reasoning is 
known, for example low relevance rates for gallates, thiomersal and sodium 
metabisulfate. Methyldibromo glutaronitrile was included in the first version of 
the ABS and later excluded.  The fragrance allergens cinnamic alcohol and 
oakmoss absolute, while not included as single allergens, are included in 
mixes on the ABS.  
The hairdressing allergens 2,5- diamtoluene sulfate and ammonium 
persulfate, both positive in >0.5% of our cohort, were common allergens in the 
Victorian series (positive rates 1% and 6%, respectively) (78). They were 
excluded from the ABS as the majority of cases were in hairdressers and this 
was felt to represent the high number of occupation-related cases seen at that 
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centre.  2,5 Diamtoluene sulfate is a primary intermediate in permanent hair 
dyes. It may be used as an alternative to PPD, however cross-reaction is 
observed in up to 50% of PPD-allergic individuals (134). Ammonium 
persulfate is an oxidiser used in hair bleach. It is a moderate to strong 
sensitiser and can elicit ACD as well as other hypersensitivity reactions such 
as urticaria and bronchospasm (135). A report from the Danish Contact 
Dermatitis Group found ammonium persulfate was the most common reaction 
after nickel in a series of 399 hairdressers presenting for patch testing with 
10.8% having a positive reaction (136). 
Our data shows the majority of reactions to these hairdressing 
allergens in the total-population were in hairdressers, however around one 
fifth of reactions were in non-hairdressers (likely greater given missing 
occupation in more than half of cases). Together with Victorian data, these 
results suggest sensitisation rates to 2,5- diamtoluene sulfate and ammonium 
persulfate in non-haridressers should be monitored with potential future 
consideration of inclusion in the ABS. 
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Comparison of patch test results in NSW and Victoria 
Objectives 
 To compare top positive and relevant allergens in NSW and Victoria 
and to compare positivity rates for common allergens between the two sites. 
 
Results 
Positive results on patch testing at The Skin Hospital’s in NSW in the 
last-ten-years were compared with patients tested at the Skin and Cancer 
Foundation in Victoria (1 January 2001 to 31 December 2010) as published 
by Toholka and colleagues (78). Baseline MOAHLFA characteristics and 
positivity rates are shown in table 5.5. There were similarities with regard to 
the most frequent positive allergens with nickel sulfate, cobalt chloride, 
Myroxylon pereirae, fragrance mix I, PPD, potassium dichromate and 
colophonium appearing in the top ten at each site (see table 5.6).  
A comparison of selected top allergens is shown in table 5.8 for 
reference. Of these allergens, all were more frequently positive in the data 
from Victoria with the exception of benzophenone 3, methyldibromo 
glutaronitrile and 2,5-diamtoluene sulfate. Using Bonferroni correction for 
multiple comparisons the significant p value was <0.001 for 54 comparisons. 
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Table 5.5 Baseline characteristics of patients undergoing patch testing at The 
Skin Hospitals in New South Wales (NSW) in the last-ten-years compared 
with reported data set from Victoria, Australia (VIC) 2001 to 2010 (78). 
Characteristic NSW (%) 
n=1584 
VIC (%) 
n=5281 
Chi-square    
p-value 
Male 531 (34) 1865 (35) 0.196 
Age > 40 years 877 (55) 2634 (50) <0.001 
Occupational cause 115 (7) 1361 (26) <0.001 
Atopic dermatitis 343 (22) 1576 (30) <0.001 
Hand dermatitis 252 (16) 1894 (36) <0.001 
Leg ulcer or dermatitis 119 (8) 444 (8) 0.273 
Facial dermatitis 370 (23) 1307 (25) 0.271 
≥1 positive reaction 441 (28) 4111 (78) <0.001 
 
Table 5.6 Top ten positive allergens by site.  
New South Wales  
(our cohort) 
Allergen 
position 
Victoria  
(from Toholka et al. 2015 (78)) 
Nickel sulfate 1 Nickel sulfate  
Cobalt chloride 2 Fragrance mix I  
Myroxylon pereirae 3 Cobalt chloride  
Fragrance mix I 4 Potassium dichromate 
p-Phenylenediamine 5 Myroxylon pereirae 
Potassium dichromate 6 Colophonium 
MCI/MI 7 Ammonium persulfate 
Dodecyl gallate  8 Cocamidopropyl betaine 
Colophonium 9 Formaldehyde 
Thiuram mix 10 p-Phenylenediamine 
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Table 5.7 Top ten relevant positive allergens by site. 
New South Wales  
(our cohort) 
Allergen 
position 
Victoria  
(from Toholka et al. 2015 (78)) 
p-Phenylenediamine 1 Fragrance mix I 
Fragrance mix I 2 Nickel sulfate 
MCI/MI 3 Potassium dichromate 
Nickel sulfate 4 Myroxylon pereirae 
Myroxylon pereirae 5 Formaldehyde 
Methylisothiazolinone 6 p-Phenylenediamine 
Thiuram mix 7 Thiuram mix 
Dodecyl gallate  8 Colophonium 
Colophonium 9 Dermatophagoides mix 
Potassium dichromate 10 Ammonium persulfate 
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Table 5.8 Comparison of patch test results at the Skin Hospital’s in New 
South Wales (NSW) versus the Skin and Cancer Foundation Victoria (VIC) 
(78). Selected allergens positive in ≥1% of patients at either site. 
Allergen NSW % 
n=1584 
VIC % 
n=5281 
Chi-square  
p-value 
Nickel sulfate 7.5 16.9 <0.001 
Cobalt chloride 3.7 10.7 <0.001 
Myroxylon pereirae 3.7 8.7 <0.001 
Fragrance mix I 3.5 11.5 <0.001 
p-Phenylenediamine 2.6 4.5 0.001 
Potassium dichromate 2.5 9.7 <0.001 
MCI/MI 2.0 3.3 0.005 
Dodecyl gallate  2.0 4.2 <0.001 
Colophonium 1.7 7.3 <0.001 
Thiuram mix 1.4 3.9 <0.001 
Methylisothiazolinone 1.3 . . 
Thiomersal  1.3 . . 
Quaternium 15 1.1 3.3 <0.001 
Ammonium persulfate 0.6 5.5 <0.001 
Cocamidopropyl betaine 0.3 5.5 <0.001 
Formaldehyde 0.8 5.3 <0.001 
Lanolin  0.4 4.1 <0.001 
Amerchol L 101 0.1 4.1 <0.001 
Dermaphagoides mix 0.1 3.7 <0.001 
Compositae mix 0.0 3.2 <0.001 
Octyl gallate   0.6 3.2 <0.001 
Diazolidinyl Urea 0.4 2.7 <0.001 
Chloroacetamide 0.5 2.6 <0.001 
Coconut diethanolamide 0.4 2.6 <0.001 
Epoxy resin 0.6 2.5 <0.001 
Tea tree oil 0.6 2.4 <0.001 
Neomycin sulfate 0.4 2.4 <0.001 
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Allergen NSW % 
n=1584 
VIC % 
n=5281 
Chi-square  
p-value 
Potassium dicyanoaurate 0.1 2.3 <0.001 
DMDM hydantoin 0.1 2.1 <0.001 
Disperse blue mix (124/106) 0.4 2.1 <0.001 
Imidazolidinyl urea 0.4 1.9 <0.001 
Sesquiterpene lactone mix 0.1 1.9 <0.001 
Hydroxyisohexyl 3-cyclohexene 
carboxaldehyde (Lyral) 
0.3 1.9 
<0.001 
Mercury 0.2 1.9 <0.001 
Budesonide 0.3 1.8 <0.001 
2-Nitro-4-phenylenediamine 0.3 1.8 <0.001 
P-tert-butylphenol formaldehyde 
resin 
0.6 1.7 
0.002 
Toluenesulfonamide formaldehyde 
resin 
0.7 1.7 
0.004 
Palladium Chloride 0.3 1.6 <0.001 
Benzophenone 4 0.2 1.6 <0.001 
Benzocaine 0.4 1.5 <0.001 
Benzalkonium chloride 0.4 1.5 <0.001 
Methyldibromo glutaronitrile 0.9 1.4 0.098 
Cetearyl alcohol 0.2 1.3 <0.001 
Mercapto mix 0.4 1.2 0.006 
Disperse blue 106 0.3 1.2 0.001 
Basic red 46 0.4 1.2 0.004 
Disperse blue 124 0.1 1.2 <0.001 
Propylene glycol 0.1 1.2 <0.001 
2,5-Diaminotoluene sulfate 0.7 1.1 0.127 
Benzophenone 3 0.6 1.1 0.079 
Black rubber mix 0.0 1.0 <0.001 
Methylprednisolone aceponate 0.1 1.0 0.001 
Tixocortol-21-pivalate 0.0 1.0 <0.001 
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Discussion 
 Comparison of baseline and MOAHLFA characteristics between our 
NSW cohort and the Victorian cohort has been discussed previously. Key 
differences are the lower positivity rate from our data and the higher 
proportion of occupational cases from Victoria. This accounts for the higher 
rate of hand dermatitis and slightly younger cohort at that site. The NSW 
cohort is also from a more recent ten-year period (2007-2016) than the 
Victorian cohort (2001-2010). The different positivity rates made direct 
comparison between the two sites difficult and the results shown in table 5.8 
demonstrate this.  
It is more useful to compare similarities and differences in the order of 
top allergens between the sites than absolute rates and, as expected, there 
are similarities in the top ten allergens between Victoria and NSW (and 
worldwide). Top-ten allergens in NSW that were not in the Victorian top-ten 
were dodecyl gallate (discussed in Chapter three, page 57 of this thesis), 
MCI/MI and thiuram mix. MCI/MI was positive in 3% of all patients in the 
Victorian cohort and ranked 13th for relevant reactions. The slight disparity 
between sites may be due to the time periods captured in the studies. Contact 
allergy to MI is increasing in recent years due to legislative change in 2005 
allowing increased concentrations in personal care products (121). MI was a 
common relevant allergen in the more recent NSW cohort, however this has 
only been tested as an individual allergen in Victoria after 2011. Thiuram mix 
was also a common allergen in the Victorian cohort, positive in 4% of patients 
and ranked 7th for relevant positive reactions. 
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 Victorian top-ten allergens not included in the NSW top ten were 
ammonium persulfate, cocamidopropyl betaine and formaldehyde. Rankings 
for these allergens in the NSW group were 20th, 50th and 17th, respectively. 
Both ammonium persulfate and formaldehyde were still common allergens in 
the NSW cohort. Ammonium persulfate was positive in 0.6% of the total 
cohort and 70% of these reactions were considered relevant. Formaldehyde 
(an allergen usually included on baseline series’) was positive in 0.8% of all 
patients and 42% of positive reactions were relevant.  
Cocamidopropyl betaine is a possible outlier. It was positive in 0.3% of 
patients and relevant in 0.1%. This allergen is a foaming agent in personal 
care products such as shampoo and liquid cleansers. Positivity to 
cocamidopropyl betaine has been associated with male gender, age over 40 
years, scalp and atopic dermatitis and hairdressing, however false positives 
and irritant reactions are very common (137). Suuronen and colleagues found 
irritant reactions in up to 39% of patients tested (138). Published sensitisation 
rates are generally low and consistent with our findings: 0.27% in England 
(139), estimated 0.19% in Germany (137), 0.2% in Finland (138). 
Cocamidopropyl betaine was positive in 6% of the total population tested in 
the Victorian study however relevant reactions were lower at 1%. The higher 
rates seen at this centre may reflect the overall high positivity rate as well as 
the high proportion of occupational cases. 
A high number of relevant positive reactions were seen to 
dermatophagoides mix in Victoria. This is not routinely tested at The Skin 
Hospitals in NSW. In their 2015 paper, Toholka and colleagues comment that 
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dermatophagoides mix was previously tested in atopics however is now 
thought to be of little clinical value (78). It is not included on the ABS. 
In summary, despite differences in baseline characteristics limiting 
direct comparison between the datasets, similarities in top allergens were 
found. Cocamidopropyl betaine is a possible outlier with high sensitisation 
rates reported in the Victorian group compared with NSW and international 
reports.   
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6. Regional allergic contact dermatitis 
Patch test results in patients with cheilitis 
Objectives 
To document the outcomes of patch testing for patients presenting with 
a dermatosis of the lips and compare findings with patients presenting without 
lip involvement. 
 
Results 
From 1 January 2007 to 31 December 2016 there were 91patients 
presenting with a dermatosis involving the lips (cheilitis). Patients with lip 
involvement were more likely to be younger (p=0.009) and female (p=0.001) 
compared with those without a dermatosis involving the lips. Concurrent 
eyelid involvement was more likely in patients with cheilitis (p<0.001) and 
hand and leg dermatitis was less likely compared with patients without cheilitis 
(p=0.005 and p=0.049, respectively). Patients with lip involvement were more 
likely to be atopic and more likely to have at least one positive patch test 
reaction (although there were no differences in the mean number of patch test 
reactions between the groups). Characteristics of patients undergoing patch 
testing with and without cheilitis are shown in table 6.1. 
There were 85 positive reactions, 65 of these to allergens on the local 
standard series or additional series and 20 to patients’ own products (see 
table 2). The most frequent reactions for patients with cheilitis were nickel 
sulfate (12%), Myroxylon pereirae (4%), cobalt chloride (4%) and fragrance 
mix I (4%). There were 37 relevant positive reactions in 15 patients who had a 
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final diagnosis of allergic contact cheilitis (16%). The most frequent relevant 
reactions after patients own products (6 patients) were to Myroxylon pereirae 
(n=4), benzophenone 3 (n=4), fragrance mix I (n=3) and benzophenone 4 
(n=2). Figure 6.1 shows a woman, aged 20 years, who had a relevant positive 
reaction to fragrance mix I. The source was cinnamic aldehyde in her lipstick. 
 
Table 6.1 Characteristics of patients undergoing patch testing in the last-ten-
years with and without lip involvement. 
Characteristic Cheilitis 
n=91 
No cheilitis 
n=1493 
Chi-square, 
Fisher’s exact or 
t-test p-value 
Mean age in years (SD) (95% CI) 39 (18.9) 
(35-43) 
44 (17.4) (43-
45) 
0.009 
Female (%) 75 (82.4) 953 (63.8) 0.001 
Atopic dermatitis (%) 36 (39.6) 307 (20.6) <0.001 
Any history of atopy (%) 52 (57.1) 463 (31.0) <0.001 
Occupational causation (%) 0 (0) 113 (7.6) 0.006 
At least one positive reaction (%) 38 (41.8) 430 (28.8) 0.009 
At least one relevant reaction (%) 15 (16.5) 202 (13.5) 0.426 
Mean number of reactions (SD) 
(95% confidence interval) 
0.92 (1.61) 
(0.59-1.26) 
0.68 (1.14) 
(0.61-0.75) 
0.116 
Distribution of dermatosis (%) 
Site Hands 5 (5.5) 247 (16.5) 0.005 
Site Eyelids 15 (16.5) 96 (6.4) <0.001 
Site Chest 2 (2.2) 29 (1.9) 0.697 
Site Arms 2 (2.2) 74 (5.0) 0.315 
Site Abdomen 2 (2.2) 16 (1.1) 0.277 
Site Back 2 (2.2) 16 (1.1) 0.277 
Site Legs 2 (2.2) 116 (7.8) 0.049 
Site Generalised 1 (1.1) 71 (4.8) 0.121 
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Figure 6.1 Cheilitis in a young woman due to allergic contact dermatitis to 
fragrance in her lipstick. Note hyperkeratosis and oedema of the lower lip. 
 
Twelve patients had one or more positive reactions to their own 
products. For 3/12 this was the only positive reaction seen. Relevant reactions 
to patients own products included lip balms, lipsticks, toothpaste and topical 
antiviral cream (“virasolve”). Non-relevant reactions to patients own products 
included deodorant, make-up primer and perfume. 
Of the 65 positive reactions to series allergens 48 were to allergens in 
the ABS (73%).  The ABS detected 24/36 relevant reactions (67%). Of the 31 
patients with at least one series allergen reaction 71% had all reactions 
detected by ABS allergens, 13% were partially evaluated (some allergens 
detected by ABS but not all) and 16% had no allergens detected by the ABS. 
Reactions to non-ABS allergens included dodecyl gallate, mercury, sodium 
metabisulfite, peppermint and copper sulfate. The local standard series (of 33 
allergens) detected 43/65 positive reactions (66%) and 16/36 relevant 
reactions (44%). 
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Table 6.2 Positive and relevant patch test reactions in patients presenting with 
cheilitis in the last-ten-years (n-91). 
Allergen ABS Local Positive Relevant 
 
% relevant / 
positive 
Benzophenone 3 Y N 4 4 100 
Benzophenone 4 Y N 2 2 100 
Advantan Y N 1 1 100 
MCI/MI Y Y 1 1 100 
Limonene Y N 1 1 100 
Quaternium 15 Y Y 1 1 100 
Eugenol * * 1 1 100 
Formaldehyde Y Y 1 1 100 
Geraniol * * 1 1 100 
Imidazolidinyl urea Y Y 1 1 100 
Toluenesulfonamide formaldehyde 
resin  
Y Y 1 1 100 
Hexylresorcinol N N 1 1 100 
Peppermint oil N N 1 1 100 
Myroxylon pereirae Y Y 5 4 80 
Fragrance mix I Y Y 5 3 60 
Colophonium Y Y 2 1 50 
Dodecyl gallate N N 2 1 50 
Mercury N N 2 1 50 
Sodium metabisulfite N N 3 1 33 
Thiuram mix Y Y 3 1 33 
Patients own products N N 19 6 32 
Cobalt chloride Y Y 4 1 25 
Nickel sulfate Y Y 11 1 9 
p-Phenylenediamine Y Y 3 0 0 
Disperse blue mix (124/106) * Y 2 0 0 
Potassium dichromate Y Y 2 0 0 
Thiomersal N N 2 0 0 
Copper sulfate N N 1 0 0 
Ethylenediamine dihydrochloride N Y 1 0 0 
ABS = Australian baseline series, Local = local baseline series, * = individual allergen not 
included on baseline series but may be present in included mixes.   
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Comparison of positive reactions for patients with and without lip 
involvement is shown in table 6.3. After adjusting for age, gender and atopy 
there was evidence that patients with cheilitis reacted more frequently to the 
sunscreens benzophenone 3 (p=0.016) and benzophenone 4 (p=0.034). 
Excluding reactions to patient own products, positive reactions to sunscreens 
accounted for 6/60 reactions (8%) in patients with lip involvement and 8/924 
reactions (1%) in patients without lip involvement (p<0.001). Sunscreens were 
listed ingredients in a number of commercially available lip balms (table 6.4). 
Other allergens more frequently positive in those with cheilitis were mercury, 
disperse blue mix and sodium metabisulfite. 
 
Table 6.3 Positive patch test reactions in patients with and without lip 
involvement. Logistic regression analysis adjusted for age, gender, atopic 
dermatitis and any atopy. 
Allergen Cheilitis 
n=91 (%) 
No cheilitis 
n=1493 (%) 
p-value 
Nickel sulfate 11 (12.1) 108 (7.2) 0.660 
Myroxylon pereirae 5 (5.5) 53 (3.5) 0.314 
Fragrance mix I 5 (5.5) 50 (3.3) 0.577 
Cobalt chloride 4 (4.4) 55 (3.7) 0.726 
Benzophenone 3 4 (4.4) 6 (0.4) 0.018 
p-Phenylenediamine 3 (3.3) 38 (2.5) 0.726 
Sodium metabisulfite 3 (3.3) 10 (0.7) 0.032 
Thiuram mix 3 (3.3) 19 (1.3) 0.128 
Colophonium 2 (2.2) 25 (1.7) 0.915 
Disperse blue mix (124/106) 2 (2.2) 4 (0.3) 0.004 
Dodecyl gallate 2 (2.2) 29 (1.9) 0.962 
Mercury 2 (2.2) 1 (0.1) 0.009 
Potassium dichromate 2 (2.2) 37 (2.5) 0.605 
Thiomersal 2 (2.2) 19 (1.3) 0.744 
Benzophenone 4 2 (2.2) 1 (0.1) 0.034 
Advantan 1 (1.1) 1 (0.1) 0.076 
MCI/MI 1 (1.1) 30 (2.0) 0.409 
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Allergen Cheilitis 
n=91 (%) 
No cheilitis 
n=1493 (%) 
p-value 
Copper sulfate 1 (1.1) 2 (0.1) 0.116 
Limonene 1 (1.1) 4 (0.3) 0.292 
Quaternium 15 1 (1.1) 16 (1.1) 0.845 
Ethylenediamine dihydrochloride 1 (1.1) 2 (0.1) 0.205 
Eugenol 1 (1.1) 1 (0.1) 0.095 
Formaldehyde 1 (1.1) 11 (0.7) 0.961 
Geraniol 1 (1.1) 5 (0.3) 0.092 
Imidazolidinyl urea 1 (1.1) 5 (0.3) 0.430 
Toluenesulfonamide formaldehyde resin  1 (1.1) 10 (0.7) 0.924 
Peppermint oil 1 (1.1) 1 (0.1) 0.997 
Hexylresorcinol 1 (1.1) 3 (0.2) 0.217 
Methylisothiazolinone 0 (0.0) 21 (1.4) 0.997 
Carba Mix 0 (0.0) 15 (1.0) 0.997 
Methyldibromo Glutaronitrile 0 (0.0) 14 (0.9) 0.997 
2,5-Diaminotoluene sulfate 0 (0.0) 11 (0.7) 0.997 
Ammonium persulfate  0 (0.0) 10 (0.7) 0.997 
Epoxy resin 0 (0.0) 10 (0.7) 0.997 
Tea tree oil 0 (0.0) 10 (0.7) 0.997 
Cinnamic alcohol 0 (0.0) 9 (0.6) 0.997 
Octyl gallate 0 (0.0) 9 (0.6) 0.997 
Chloroacetamide 0 (0.0) 8 (0.5) 0.997 
Coconut diethanolamide 0 (0.0) 7 (0.5) 0.997 
Diazolidinyl urea 0 (0.0) 7 (0.5) 0.997 
Mercapto mix 0 (0.0) 7 (0.5) 0.997 
Neomycin sulfate 0 (0.0) 7 (0.5) 0.997 
Oakmoss absolute 0 (0.0) 7 (0.5) 0.997 
 
Table 6.4 Sunscreen ingredients in lip balms. Extracted from Priceline 
Pharmacy website July 2017 (140). 
Product Sunscreen ingredient 
Lip Smacker Refresh Gloss - Coke Vanilla 
& Coke Classic 12mL 
Titanium dioxide 
Carmex Lip Balm Strawberry Click Stick™ 
SPF15 4.3g 
Ethylhexyl methoxycinnamate, 
Benzophenone 3 
Models Prefer Tinted Lip Balm 3g Titanium dioxide 
Carmex Lip Balm Original Click Stick™ 
SPF15 4.3g 
Ethylhexyl methoxycinnamate, 
Benzophenone 3 
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Product Sunscreen ingredient 
Blistex Happy Lips Melon Lip Balm SPF 15 
3.7g 
Ethylhexyl methoxycinnamate, 
Benzophenone 3 
Carmex Jasmine Green Tea Moisturising 
Lip Balm Squeeze Tube SPF15 10g 
Ethylhexyl methoxycinnamate, 
Benzophenone 3 
Blistex Pearl Soft & Silky Balm 7g Titanium dioxide 
Manuka Doctor ApiNourish Lip Balm 
SPF15 15mL 
 
Ethylhexyl methoxycinnamate, 
Benzophenone 3, Diethylamino 
hydroxybenzoyl hexyl benzoate 
Sun Bum Lip Balm Pink Grape Fruit, 
Pomegranite, Mango, Lime, Coconut and 
Bannana SPF15 4.3g 
Zinc oxide 
S.o.s Labbra Lip Rescue Balm 5g Ethylhexyl methoxycinnamate, zinc oxide 
Rimmel Lasting Finish By Kate Moss Lip 
Balm 4g 
Ethylhexyl methoxycinnamate 
Luv Ur Skin Vanilla Cream Lip Balm 10mL Titanium dioxide 
Natio Moisturising Lip Balm SPF 50+ 4g Octocrylene, Benzophenone 3, Butyl 
methoxydibenzoylmethane, Ethylhexyl 
methoxycinnamate 
Blistex Happy Lips Strawberry and Mango 
Lip Balm SPF 15 3.7g 
Ethylhexyl methoxycinnamate, 
Benzophenone 3 
Blistex Deep Renewal Moisturise and 
Revitalise SPF15 3.7g 
Ethylhexyl methoxycinnamate, 
Benzophenone 3 
Girl Lane Paw Paw Lip Balm SPF15+ 15g Ethylhexyl methoxycinnamate, Octocrylene 
Maybelline Baby Lips SPF 20 4g Ethylhexyl methoxycinnamate 
Maybelline Baby Lips Loves Color SPF 16 
4.5g 
Ethylhexyl methoxycinnamate 
Blistex Lip Conditioner SPF 15 7g Ethylhexyl methoxycinnamate, 
Benzophenone 3 
Chapstick Lip Conditioner SPF15 4.2g 
 
Ethylhexyl methoxycinnamate, 
Benzophenone 3 
Nivea Fruity Shine Strawberry 4.8g Ethylhexyl methoxycinnamate 
Manuka Doctor ApiRefine Lip Enhancer 
15mL 
Titanium dioxide 
Chapstick Lip Balm Classic SPF15 4.2g Octyl methoxycinnamate, Benzophenone 3 
 
Palmer's Cocoa Butter Dark Chocolate & 
Mint Lip Balm SPF 15 4g 
 
Ethylhexyl methoxycinnamate, 
Benzophenone 3 
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Product Sunscreen ingredient 
Nivea Sun Protect SPF30 4.8g 
 
Ethylhexyl methoxycinnamate, 
Benzophenone 3, Octocrylene, Titanium 
dioxide 
Palmer's Cocoa Butter Formula Lip Balm 
Sunscreen Stick SPF 15 4g 
Ethylhexyl methoxycinnamate, 
Benzophenone 3 
Carmex Moisture Plus Ultra Hydrating Lip 
Balm Peach Sheer SPF15 2g 
Ethylhexyl methoxycinnamate, 
Benzophenone 3 
Carmex Moisture Plus Ultra Hydrating Lip 
Balm Pink Sheer Tint SPF15 2g 
Ethylhexyl methoxycinnamate, 
Benzophenone 3 
Nivea Soft Rose Lip Balm 4.8g Etheylhexyl methoxycinnamate, Butyl 
methoxydibenzoylmethane 
Blistex Five Way Lip Protection SPF30+ 
4.3g 
Homosalate, Octyl methoxycinnamate, Octyl 
salicylate, Benzophenone 3 
Carmex Moisture Plus Ultra Hydrating Lip 
Balm Clear SPF15 2g 
 
Ethylhexyl methoxycinnamate, 
Benzophenone 3 
Blistex Intensive Repair SPF15 7g 
 
Ethylhexyl methoxycinnamate, 
Benzophenone 3 
Blistex Lip Conditioning Balm SPF 20 4.3g Octyl methoxycinnamate 
Nivea Hydro Care 4.8g Ethylhexyl methoxycinnamate 
Blistex Ultra Lip Balm SPF 30+ 4.2g 
 
Octyl methoxycinnamate, Benzophenone 3, 
Octyl salicylate, Menthyl anthranilate, 
Homosalate 
Chapstick Lip Balm Strawberry SPF15 4.2g Ethylhexyl methoxycinnamate, 
Benzophenone 3 
Palmer's Cocoa Butter Dark Chocolate & 
Cherry Tinted Lip Balm SPF 15 4g 
Ethylhexyl methoxycinnamate, 
Benzophenone 3 
Nivea Pearly Shine 4.8g Ethylhexyl methoxycinnamate 
Nivea Repair & Protection SPF15 4.8g Ethylhexyl methoxycinnamate, Avobenzone 
Blistex Medicated Relief Lip Ointment 6g Benzophenone 3 
Natio Moisturising Lip Balm SPF 30+ 4g 
 
Ethylhexyl methoxycinnamate, Octocrylene, 
Benzophenone 3, Avobenzone 
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Discussion  
Cheilitis is characterised by inflammation of the lip or vermillion. A 
number of inflammatory patterns are recognised including dermatitis (which 
may be irritant, atopic, allergic or seborrhoeic), lichenoid (lichen planus, 
cutaneous lupus erythematosus) and granulomatous (orofacial 
granulomatosis, Crohn disease, sarcoidosis). Cheilitis may also be caused by 
infection, trauma (for example exfoliative cheilitis) and nutritional deficiencies. 
Chronic sun exposure may lead to dysplasia of the cutaneous lip, termed 
actinic cheilitis, although this condition is not an indication for patch testing.  
We found 16% of patients with cheilitis seen in the patch testing clinics 
had a final diagnosis of allergic contact cheilitis (ACC). Freeman and 
Stephens reported a series of 75 patients with cheilitis seen at The Skin 
Hospital in Darlinghurst (previously named The Skin and Cancer Foundation 
Australia) between 1991 and 1997 (141). In this study the final diagnoses 
were irritant contact dermatitis (36%), ACC (25%), atopic dermatitis (19%), 
unspecified dermatitis (9%), non-dermatitis causes (9%) and seborrhoeic 
dermatitis (1%). Similar to our findings there was a female predominance; 
71% of patients referred with cheilitis and 89% of those with a final diagnosis 
of ACC were female and this likely represents use of cosmetics by women 
leading to lip allergen exposure. The most common cause for ACC in 
Freeman’s study was medicaments (5 patients) followed by fragrance or 
lanolin in lipsticks (n=4), sunscreens benzophenone 3 and avobenzone (n=3), 
toothpaste allergens triclosan and peppermint (n=3), colophonium (n=2) and 
toluenesulfonamide formaldehyde resin in nail varnish (n=2). Twelve of the 19 
were fully evaluated by the standard series alone (63%) and this is similar to 
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the proportion of cases diagnosed by the ABS in our group. These findings 
highlight the importance of additional allergens and series tailored to the 
clinical presentation in patients with cheilitis. For example, additional dental 
series, sunscreen series, fragrance/flavouring series and cosmetic series may 
be appropriate. Freeman’s study only reported relevant positive allergens and 
so it is difficult to compare directly with our findings however, fragrances and 
sunscreens were also top relevant allergens in our patients with cheilitis.  
In a retrospective study of 146 patients with cheilitis seen over a 19-
year period (1982-2001) in the United Kingdom, Strauss and Orton 
documented findings similar to ours (69). A relevant positive reaction was 
found in 15% of patients, 95% of whom were women. Top allergens were 
fragrance mix, shellac, colophonium and Myroxylon pereirae. Lipsticks and lip 
balms were the most common exposure source, and the authors propose a 
specialised lips cosmetic series (table 6.5). A significant proportion of patients 
reacted to their own products only (18%). 
A report from the NACDG found 38% of patients presenting for patch 
testing with cheilitis had a relevant positive reaction and a final diagnosis of 
ACC, however this study included patients with “possible” and “probable” 
relevant reactions in addition to those with “definite” relevant reactions (67). 
Of the 127 relevant reactions, the most were to fragrance mix I (n=18) 
followed by Myroxylon pereirae (n=14), nickel sulfate (n=13), sodium gold 
thiosulfate (n=8), neomycin sulfate (n=7) and cobalt chloride (n=6). Sixty-four 
percent of patients were fully evaluated with the NACDG baseline series. 
Most reactions were in women (84%).  
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Table 6.5 Lip cosmetic series proposed by Strauss and Orton (69). 
Allergen Concentration (vehicle) 
Ozokerite wax 30% (petrolatum) 
Beeswax 30% (petrolatum) 
Propylene glycol 20% (petrolatum) 
Cetyl palmitate 30% (petrolatum) 
Myristyl lactate 0.5% (petrolatum) 
Candelilla wax 30% (petrolatum) 
Castor oil 30% (petrolatum) 
Trilaurin 0.5% (petrolatum) 
Cetyl alcohol 30% (petrolatum) 
Microcrytalline wax 30% (petrolatum) 
Isopropyl isostearate 0.05% (petrolatum) 
Propyl gallate 0.1% (petrolatum) 
Liquid paraffin 100% (petrolatum) 
Shellac 20% (alcohol) 
Eosin 50% (petrolatum) 
 
In 202 patients with cheilitis at a patch testing clinic in Singapore, the 
most common positive reactions were to nickel sulfate (18%), patients own 
cosmetics (13%) and ricinoleic acid (castor oil, 11%) and the most relevant 
reactions were to patients own cosmetics (34%), ricinoleic acid (22%) and 
fragrance mix (12%) (142). Lipsticks and lip balms were the commonest 
cause of ACC. Nickel was also the most common positive allergen in a study 
from Athens (32%) (143). Fragrances and other ingredients in lip cosmetics 
were the most common cause of allergic contact cheilitis in two reports from 
Italy (144, 145). Fragrance mix, Myroxylon pereirae and gallates were the top 
allergens in a Mayo Clinic study of cheilitis (146). 
107 
 
In summary, the common allergens reported in ACC are nickel, 
fragrances (including Myroxylon pereirae) and colophonium (table 6.6). Nickel 
is a common sensitiser in the general population, particularly for women. The 
reported proportions of relevant from positive reactions in patients with 
cheilitis range widely from 6 to 50% (9% in our data) (142-146). Described 
causes of ACC to nickel include sucking on metal objects, metal lipstick or 
cosmetic cases, metal in instrument mouthpieces and nickel impurities in lip 
cosmetics. It is unknown how strong the evidence was for the source of nickel 
in these cases, for example whether repeated open application or stop-restart 
use tests were undertaken, and interpretation of relevance may be subjective 
and vary between clinicians. 
Fragrances are common ingredients in lip and other cosmetics. 
Myroxylon pereirae (balsam of Peru) is used as a fragrance and flavouring 
agent and smells of cinnamon and vanilla. Food is a potential exposure 
source as Myroxylon pereirae may be found in foods such as spices, soft 
drink, citrus peel, tomatoes and baked goods (147). It may also be used to 
flavor toothpaste and mouthwash. Two cases of ACD to Myroxylon pereirae 
contained in the popular lip balm Lucas Pawpaw Ointment have been 
reported in Australia (148). Colophonium (colophony or rosin) is a sticky 
substance, presumably added to lip cosmetics as an adhesive. It has been 
documented as a cause of allergic contact cheilitis due to lipsticks (149). 
Colophonium may cross react with Myroxylon pereirae (4). 
 Atopy may be associated with cheilitis. We found patients with cheilitis 
were more likely to have a history of atopic dermatitis or any atopy than those 
presenting with other dermatoses. Katsarou et al. found nearly half of patients 
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with cheilitis in the patch-testing clinic had a history of atopy (143). Zug et al. 
found patients with a final diagnosis of ACC were less likely to have a history 
of atopy (28%) compared with all patients with cheilitis (37%), however 
analysis did not control for potential confounders (67). The association with 
atopy may explain the higher rate of concurrent eyelid involvement seen in 
our cohort, however this may also be secondary to the young female 
demographic in those with cheilitis who may have irritant or allergic eyelid 
dermatitis due to cosmetic use, fragrance or nickel. 
All of the above studies confirmed the value of testing patient’s own 
products in the assessment of allergic contact cheilitis. Examples of relevant 
products include lipsticks, lip balms, medicaments and toothpaste. Most 
cosmetics designed to be left on the skin can be tested “as is” on the skin 
(that is, without dilution). Toothpaste however, may lead to irritant reactions if 
tested in this manner due to presence of detergents and abrasives (150) and 
positive reactions should be confirmed with serial dilution and use tests. 
We found evidence that patients with cheilitis were more likely to react 
to sunscreens benzophenone 3 and benzophenone 4 compared with patients 
seen in the patch-testing clinic without lip involvement. Relevant reactions to 
sunscreens are documented in studies of allergic contact cheilitis from 
Australia and North America (67, 141, 146). Case reports of ACC due to 
benzophenone 3, have also been published from Spain, North America and 
the United Kingdom (75, 151-153). Australia has one of the highest rates of 
skin cancer in the world and sunscreen use may be more widely adopted than 
in other countries (154). This increased exposure to sunscreens in Australia 
may contribute to sensitisation and subsequent ACD.   
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Table 6.6 Studies of allergic contact cheilitis (ACC).  
Study – Authors, 
date 
ACC 
% 
Female 
% 
Atopy 
% 
Top relevant allergens 
Freeman, 1999 
(141) 
25 71 NR Benzophenone 3, lanolin, 
fragrance mix, 
colophonium, triclosan 
Lim, 2000 (142) 34 90 33 Own cosmetics, ricinoleic 
acid (castor oil), own 
toothpaste, fragrance mix, 
Myroxylon pereirae 
Strauss, 2003 (69) 15 95  NR Fragrance mix, shellac, 
colophonium, Myroxylon 
pereirae, own lipstick 
Zoli, 2006 (144) 18 71 35 Fragrance mix, nickel 
sulfate, methyldibromo 
gluatronitrile, Myroxylon 
pereirae, own cosmetic 
Katsarou, 2008 
(143) 
NR 76 46 NR 
Zug, 2008 (67) 38 84 37 Fragrance mix, Myroxylon 
pereirae, nickel sulfate, 
sodium gold thiosulfate, 
neomycin sulfate 
Milanesi, 2016 
(145) 
37 64 NR Fragrance mix, eugenol, 
MCI/MI, propolis  
O’Gorman, 2016 
(146) 
45 77 NR Fragrance mix, Myroxylon 
pereirae, dodecyl gallate, 
octyl gallate, benzoic acid 
Current study 16 82 57 Own products, Myroxylon 
pereirae, benzophenone 
3, fragrance mix, 
bezophenone 4 
NR – not reported  
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We found sunscreens, particularly bezophenone 3 and ethylhexyl 
methoxycinnamate, to be common ingredients in commercially available lip 
balms in Australia. Interestingly, ethyhexyl methoxycinnamate is structurally 
related to cinnamon-related fragrances, which can be found in foods and lip 
cosmetics, however, there is little evidence of cross reactivity (155). 
Benzophenone 3, also known as oxybenzone, is an ultraviolet B and short-
wave ultraviolet A filter that is commonly used in sunscreens as well as 
various cosmetics and personal care products to prevent ultraviolet-induced 
product degradation. It was the most common photoallergen in a review of 
2,715 patients undergoing photopatch testing at St John’s Institute of 
Dermatology (156). 
We found evidence that patients with cheilitis were more likely to react 
to mercury, sodium metabisulfate and disperse blue mix than patients with 
other dermatoses, however none of the reactions to disperse blue mix were 
considered relevant. The first case was a 65-year-old man with a two-year 
history of cheilitis who also has a strong positive reaction to dodecyl gallate. 
The gallate was an ingredient in his lip balm and the relevant allergen. The 
second case was a 47-year-old man with lichen planus or the lips and oral 
mucosa. In addition to a strong positive reaction to disperse blue he had 
positive reactions to sodium metabisulfite (unknown relevance) and to 
mercury, which was considered relevant as a component of amalgam fillings. 
Disperse blue dyes are textile dyes however, according to the Households 
Products Database, historically disperse blue 1 has been found in “Crest 
Rejuvenating Effects Fluoride Anticavity Toothpaste”. Email correspondence 
from Colgate on 29th August 2017 denied use of disperse dyes in current 
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products. The food dye Brilliant Blue FCF is found in currently available 
toothpastes but has an unrelated chemical structure to disperse blue 106 or 
124 (see figure 6.2). 
 
Figure 6.2 Comparison of molecular structure of brilliant blue FCF, disperse 
blue 106 and disperse blue 124. 
 
 
 
The limitations of this analysis include the overall low numbers of 
positive reactions seen, confounding factors such as age and gender and the 
retrospective design, which may contribute to measurement bias due to 
incomplete data recording (although this is non-differential between the 
comparison groups).  
In conclusion, our study and the available literature confirm women 
present with ACC more frequently than men and suggest sunscreens 
(particularly benzophenone 3) should be considered for Australians 
presenting with a possible diagnosis of ACC. Testing with a baseline series 
alone is unlikely to be sufficient to evaluate these cases and it is important to 
test the patient’s own products as well as additional series’ particularly 
cosmetic and fragrance allergens.  
Brilliant Blue FCF 
C37H34N2Na2O9S3 
Disperse blue 106 
C14H17N5O3S 
Disperse blue 124 
C16H19N5O4S 
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Patch test results in patients with anogenital dermatoses 
Objectives 
The primary objective of this analysis was to document the outcomes 
of patch testing for patients presenting with a dermatosis of the anogenital 
region.  
 
Results 
In the total-population (1/02/2002 to 31/12/2016), 64 patients with 
anogenital dermatoses were patch tested at The Skin Hospitals in Darlighurst 
and Westmead. Thirty-seven were female accounting for 56% and the 
average age was 49 years (SD 17.7, range 26 to 82). The most common 
diagnosis was dermatitis (ACD, atopic and irritant contact dermatitis) followed 
by psoriasis and lichen sclerosus. Dermatologist diagnoses before and after 
patch testing are shown in Figure 6.3. 
 The baseline series was tested in 63/64 patients. Specialist series 
tested included antimicrobials and preservatives (n=37), corticosteroids 
(n=36), face series (n=33), fungicides (n=14) and perfumes and flavours 
(n=9). 
Thirty-four patients had at least one positive reaction (53%) and 19 had 
at least one relevant reaction (30%). The most common allergens testing 
positive on patch testing were nickel (n=10), fragrance mix I (n=8), Myroxylon 
pereirae (n=8), docecyl gallate (n=6) and cobalt chloride (n=6). The most 
frequent relevant allergens were fragrance mix I (n=6), Myroxylon pereirae 
(n=5), cocamidopropyl betaine (n=2) and benzocaine (n=2). Positive and 
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relevant results are shown in table 6.7. Six patients tested positive to their 
own products (9%) and four of these reactions were considered relevant. 
 
Figure 6.3 Diagnoses for patients with anogenital dermatoses pre and post 
patch testing. 
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Table 6.7 Positive and relevant patch test results in patients with anogenital 
dermatoses (n=64). 
Allergen Positive Relevant % relevant/ 
positive 
Nickel sulfate 10 0 0 
Fragrance mix I 8 6 75 
Myroxylon pereirae 8 5 63 
Patient’s own product 6 4 67 
Dodecyl gallate 6 1 17 
Cobalt chloride 6 0 0 
Benzocaine 3 2 67 
Cocamidopropyl betaine 3 2 67 
p-Phenylenediamine 3 0 0 
Thiomersal 3 0 0 
Benzalkonium chloride 2 1 50 
Diazolidinyl urea 2 1 50 
Methyldibromo glutaronitrile 2 1 50 
Hydrozole 2 1 50 
Sodium metabisulfate 2 1 50 
Elidel cream (without pimecrolimus) 2 0 0 
Imidazolidinyl urea 2 0 0 
Potassium dichromate 2 0 0 
Hexahydro-1,3,5-tris-(2-
hydroxyethyl)triazine 
1 1 100 
Coconut diethanolamide 1 1 100 
Formaldehyde 1 1 100 
MCI/MI 1 1 100 
Quaternium 15 1 1 100 
Tineafax cream 1 1 100 
Lanolin  1 1 100 
4-tert-butylphenol formadelhyde resin 1 0 0 
Benzoyl peroxide 1 0 0 
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Allergen Positive Relevant % relevant/ 
positive 
Butyl-4-hydrobenzoate 1 0 0 
Chloroacetamide 1 0 0 
Chlorocresol 1 0 0 
Chloroquinadol 1 0 0 
Colophonium 1 0 0 
Copper sulfate 1 0 0 
Epoxy resin 1 0 0 
Goldsodium thiosulfate 1 0 0 
Propyl-4-hydroxybenzoate 1 0 0 
Sorbitan monooleate 1 0 0 
Total 91 33 - 
 
 
Discussion 
A number of reports focus on contact dermatitis of the vulva in women, 
however men also present with anogenital rashes suspicious for ACD. 
Compared with the total population seen during this period (see chapter 3) the 
group with anogenital skin disease had a lower proportion of females (56% 
versus 67%) and an older mean age (49 versus 44 years). A report from the 
NACDG database found no significant difference in the proportion of females 
when grouped by anogenital involvement (61% female in those with 
anogenital involvement, 65% female without anogenital involvement, p=0.1) 
(59). This report found female patients were two times more likely to have a 
final diagnosis other than dermatitis (relative risk 1.99, p<0.001) compared 
with men. Lichenoid disorders inlcuduing lichen sclerosus are common 
anogenital dermatoses in women. Despite antoimmune aetiology, women with 
lichen sclerosus with positive patch tests may improve with allergen 
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avoidance (157). The top relevant allergens found in the NACDG study were 
similar to ours: fragrance mix, Myroxylon pereirae, nickel sulfate, cinnamic 
aldehyde, neomycin sulfate and dibucaine. Medicaments and corticosteroids 
were the most common allergen sources. We found 30% of patients 
presenting with anogenital involvement had at least one relevant positive 
allergen and comparative rates from the literature vary widely; 17% in Belgium 
(158) to 73% in Scotland (159). Overall, in our clinics patch testing seemed to 
refute a suspected diagnosis of ACD in favour of other forms of dermatitis or 
psoriasis. 
The Australian literature describing patch testing in patients with 
anogenital dermatoses include an early report from Victoria where the most 
common positive allergens were similar to ours: nickel (22%), fragrances 
(12%), cobalt chloride (6%) and caine mix (6%) (160). Medicaments and 
fragrances were the top relevant allergens. A prospective study from Adelaide 
found 44% of women with vulval pruritus had at least one relevant positive 
reaction on patch testing (58).  A final diagnosis of ACD was associated with 
severity of pruritus, history of using multiple topical products and skin biopsy 
showing dermatitis. A presentation by Slape and Chow in 2017 found around 
half of patients presenting with anogenital dermatoses at a patch testing clinic 
at Liverpool Hospital in NSW had a relevant allergen found (161). The top 
allergens were medicaments and personal care products. 
Sensitisation to fragrances is commonly reported in this group (60, 162, 
163). In a series of 1,238 patients seen for genital dermatoses at 
Massachusetts General Hospital Contact Dermatitis Clinic the top allergens 
were Myroxylon pereirae (11%), fragrance mix I (8%), balsam of Tolu (8%), 
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phenylmercuric acetate (8%), and neomycin (5%) (60). Fragrances are a 
common additive to personal care products designed for use in the genital 
region. A study from the Netherlands found spices and flavours including 
nutmeg, coriander powder, onion powder and curry powder were the most 
relevant allergens in patients with vulval dermatoses and avoidance of these 
spices in food lead to significant improvement (164). This is a unique and 
interesting finding. The authors suggest that fragrance mix and Myroxylon 
pereirae may be markers for spice allergy and that spice contact with the 
anogenital region occurs via excretion in urine and faeces. The authors have 
also reported a case of vulval dermatitis due to peppermint oil in herbal tea 
(165). 
Caine anaesthetics are another commonly reported cause of ACD in 
the anogenital region (66, 166, 167), likely due to presence in topical 
haemorrhoid preparations. Benzocaine is also an ingredient in Vagisil® 
(Combe Incorporated, New York), an over the counter cream marketed for 
vaginal irritation. Vagisil® was a common allergen in the Adelaide study of 
vulval pruritus (58). In addition to the baseline series, it is recommended that 
testing includes a topical medicament and anaesthetic series as well as the 
patient’s own products (168). 
The corticosteroid series was added for over half of patients however 
no cases of anogenital ACD due to corticosteroids were seen. Further, 
Brenan and colleagues patch-tested 50 patients with vulval dermatoses in 
Victoria with the corticosteroid series and despite widespread corticosteroid 
use in their patients there was only one positive reaction to budesonide, which 
was not considered relevant (160). We saw three cases of sensitisation to 
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antifungal preparations and two of these were relevant. Contact reactions to 
imidazole antifungals are often irritant, however ACD may occur to 
components of the vehicle or the active ingredient (usually miconazole) (169, 
170). 
Preservatives are common ingredients in personal care products and 
topical medicaments and in keeping with the literature were implicated in 
anogenital ACD in our series. We saw relevant reactions to formaldehyde and 
formaldehyde-releasing preservatives (quaternium 15, imidazolidinyl urea, 
diazolidinyl urea) and other preservatives including methyldibromo 
glutaronitrile and sodium metabisulfite. There was one case of anogenital 
ACD caused by MCI/MI and this has been reported in the literature due to 
content in moist flushable wipes (62). In addition to personal care products 
sanitary pads have been implicated as a source of preservative allergy in 
women (65). 
 We found 16% of patients had a positive patch test reaction to nickel 
however none of these reactions were considered relevant. Lucke et al. 
reviewed women with vulval dermatoses and argued that nickel may be an 
important allergen after finding eight women with positive nickel patch tests 
who improved after nickel avoidance (159). The relevance of nickel sensitivity 
in these cases is debated as the majority have no direct nickel contact with 
the anogenital region other than the potential for trace metals in recycled 
paper used to make toilet paper (160). Some propose nickel transfer from the 
hands is the allergen source. Systemic contact dermatitis is another proposed 
mechanism and a prospective study from Denmark found 3/3 patients with 
anogenital dermatitis and 21/31 (68%) with vesicular hand eczema 
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experienced long term improvement after adoption of a low-nickel diet, 
however there was no control group in this study and numbers are low (171). 
 One patient in our cohort experienced contact urticaria; a 19-year-old 
female who reacted to her own moisturising cream. More commonly, contact 
urticaria affecting the genitalia is reported due to seminal fluid or latex in 
condoms (158). 
 In conclusion, the top positive and relevant allergens seen in our 
patients with anogenital disease were in concordance with other reports from 
Australia and the rest of the world. In particular, reactions to fragrance mix 
and Myroxylon pereirae are common in the majority of studies and ideally 
products used on anogenital skin should be fragrance free. Medicaments are 
commonly implicated (likely due to anaesthetic, fragrance and preservative 
content) and testing patient’s own products is imperative. We found no 
relevance of nickel reactions however literature review suggests, in patients 
with anogenital disease and a positive patch test to nickel without another 
identified cause, nickel avoidance including trial of low nickel diet may be 
beneficial. 
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7. Key findings and implications for 
future research  
Demographics, allergens and the Australian Baseline Series 
 
• The majority of patients presenting for patch testing were adults and more 
women present compared with men. Analysis of other MOAHLFA 
characteristics found lower rates of occupational and hand dermatitis 
compared with data from Victoria (which was used to formulate the ABS). 
Therefore, our data provided useful information on the performance of the 
ABS in a general patch-testing clinic with less specialisation in 
occupational dermatology. 
• Overall the ABS detected 72.9% of all relevant reactions and cases of 
allergic contact dermatitis. The current use of differing baseline series’ at 
Darlinghurst and Westmead sites introduces limitations with comparative 
research. It would also be more cost efficient for the same series to be 
used at each site. Given the ABS performed well in our cohort, use of this 
series seems appropriate however, the costs of testing with additional 
allergens in a larger baseline series needs to be considered.  
• Regarding the use of baseline series’ in specific age groups the ABS 
performed least well in adults ≥65 years and despite adequate allergen 
detection using the ABS, a truncated baseline series is recommended for 
children. Further study of contact sensitisation in Australian children and 
older adults is recommended to confirm the most relevant allergens in 
these age groups. 
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• Despite the low number of occupational cases included in our study, high 
positivity rates to hairdressing allergens ammonium persulfate and 2,5 
diamtoluene sulfate were found and suggest further monitoring of 
sensitisation rates to these allergens in non-hairdressers. 
• The overall positivity rate in our data was relatively low at 28%, particularly 
compared with reports from Victoria (78%). This may represent less 
stringent triaging of referrals at The Skin Hospital. Cost effectiveness is 
maximal when the positivity rate is between 30 and 68% and further 
research into the referral pathways and indications for patch testing at The 
Skin Hospital may have the potential to improve efficiency.  
• Our top allergens were in keeping with other Australian and International 
reports, with the possible exception of dodecyl gallate, which had more 
positive and relevant reactions than expected. This warrants ongoing 
surveillance as this allergen is excluded from most baseline series’ 
including the ABS. 
• Results confirmed the importance of testing patient’s own products and the 
addition of specialised series based on the clinical presentation of the 
dermatosis in question, even when using an extended baseline series 
such as the ABS. 
• Patch test surveillance is essential to detect the most important and 
relevant allergens and identify trends in contact sensitisation. For this to be 
done efficiently, recording of reactions in a comprehensive database is 
recommended. This study identified issues with data collection from the 
current database. It is recommended that the process of recording patch 
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test results in Darlinghurst and Westmead be reviewed as it is likely that 
the database requires updating. 
Trends in patch test results 
 
• Nickel sensitisation was highest in young adults and there was a trend 
towards increasing sensitiation converse to some International reports. 
This finding warrants ongoing surveillance as there is no current legislation 
in place in Australia to regulate the use of nickel in jewellery and other 
products in contact with the skin. 
• Chromate allergy had increased in young women and there is some 
supportive evidence in the literature for a changing demographic in 
chromate allergy, possibly due to exposure from leather shoes and 
clothing.  
Regional contact dermatitis 
 
• Sunscreens, particularly benzophenone 3, are common ingredients in 
topical lip cosmetics and should be considered as a potential cause of 
allergic contact cheilitis in Australians presenting for patch testing. 
• Causes of ACD involving the anogenital skin were similar to International 
reports including fragrance mix, Myroxylon pereirae and medicaments.  
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Appendices 
Appendix one: Baseline series used at testing sites in Darlinghurst and 
Westmead 
Allergen Darlinghurst  
Concentration and 
vehicle 
Westmead  
Concentration and 
vehicle 
Potassium dichromate 0.25% pet 0.5% pet 
Nickel sulfate 5% pet 5% pet 
p-Phenylenediamine  1% pet 1% pet 
Myroxylon pereirae 25% pet 25% pet 
Neomycin sulfate 20% pet 20% pet 
Parabens mix 12% pet 12% pet 
Colophonium 20% pet 20% pet 
Lanolin 30% pet 30% pet 
Epoxy resin  1% pet 1% pet 
Mercapto mix 2% pet 2% pet 
Thiuram mix 1% pet 1% pet 
Fragrance mix I 8% pet 8% pet 
Quaternium 15 1% pet 1% pet 
Formaldehyde 1% aq 1% aq 
Chlorocresol   1% pet 1% pet 
Mercaptobenzothiazole  2% pet 2% pet 
Imidazolidinyl urea 2% pet 2% pet 
Methylisothiazolinone 0.2% aq 0.2% aq 
MCI/MI  0.02% aq 0.02% aq 
Toluenesulfonamide 
formaldehyde resin  
10% pet 10% pet 
Carba Mix 3 % pet 3 % pet 
Cobalt chloride 1% pet 1% pet 
4-tert-butylphenol formaldehyde 
resin  
1% pet 1% pet 
Sesquiterpene lactone mix 0.1% pet Not included 
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Allergen Darlinghurst  
Concentration and 
vehicle 
Westmead  
Concentration and 
vehicle 
Budesonide 0.1% pet Not included 
Tixocortol-21-pivalate 1% pet Not included 
Black rubber mix 0.6% pet Not included 
Disperse blue mix (124/106) 1% pet Not included 
Propylene glycol 20% aq Not included 
Benzyl alcohol 1% pet Not included 
Tea tree oil 10% pet Not included 
Fragrance mix II 14% pet Not included 
Diazolidinyl Urea  2% pet Not included 
Primin Not included 0.01% pet 
N-Isopropyl-N-phenyl-4-
phenylenediamine 
Not included 0.1% pet 
Ethylenediamine dihydrochloride Not included 1% pet 
Castor oil Not included 1mL 
Epoxy acrylate Not included 0.5 pet 
Benzocaine Not included 5% pet 
Methyl dibromoglutaronitrile Not included 0.5% pet 
Pet = petrolatum; Aq = aqueous  
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Appendix two: Specialised series available at testing sites in Darlinghurst 
and Westmead 
 
Antimicrobials and preservatives 
Adhesives (methacrylates) 
Bakers 
Corticosteroids 
Cosmetics 
Dental 
Face 
Hairdressing 
Isocyanates 
Local anaesthetics 
Medicaments 
Mercurials 
Metals 
 
Oil and cooling 
Organic dyes 
Perfumes and flavours 
Pesticides 
Photoallergens 
Photographic chemicals 
Plants 
Plastics and glues 
Rubber 
Shoe 
Sunscreen 
Textiles 
Toothpaste 
 
  
 Appendix three: Comparison of baseline series around the world 
 
Allergen Australian baseline 
series  
European baseline 
series 
International 
baseline series 
Japanese baseline 
series 
North American 
baseline series 
Potassium dichromate 0.5% pet 0.5% pet 0.5% pet 0.5% pet 0.25% pet 
Nickel sulfate 5% pet 5% pet 2.5% pet 2.5% pet 2.5% pet 
p-Phenylenediamine  1% pet 1% pet 1% pet 1% pet 1% pet 
Balsam Peru 25% pet 25% pet 25% pet 25% pet 25% pet 
Neomycin sulfate 20% pet 20% pet 20% pet 20% pet 20% pet 
Parabens mix 12% pet 16% pet 16% pet 15% pet 12% pet 
Colophonium 20% pet 20% pet 20% pet 20% pet 20% pet 
Lanolin 30% pet 30% pet 30% pet 30% pet Not included 
Epoxy resin  1% pet 1% pet 1% pet 1% pet 1% pet 
Mercapto mix 2% pet 2% pet 2% pet 2% pet 1% pet 
Thiuram mix 1% pet 1% pet 1% pet 1.25% pet 1% pet 
Fragrance mix I 8% pet 8% pet 8% pet 8% pet 8% pet 
Quaternium 15 1% pet 1% pet 2% pet Not included 2% pet 
Formaldehyde 1% aq 2% aq 2% aq 1% aq 2% aq 
Chlorocresol   1% pet Not included Not included Not included Not included 
Mercaptobenzothiazole  2% pet 2% pet 2% pet Not included 1% pet 
Imidazolidinyl urea 2% pet Not included 2% pet Not included 2% pet 
Methylisothiazolinone 0.2% aq 0.2% aq 0.01% aq Not included 0.2% aq 
MCI/MI  0.02% aq 0.02% aq 0.02% aq 0.01% aq 0.02% aq 
Toluenesulfonamide formaldehyde resin  10% pet Not included 10% pet Not included 10% pet 
Carba Mix 3 % pet Not included 3% pet Not included 3% pet 
Cobalt chloride 1% pet 1% pet 1% pet 1% pet 1% pet 
4-tert-butylphenol formaldehyde resin  1% pet 1% pet 1% pet 1% pet 1% pet 
Sesquiterpene lactone mix 0.1% pet 0.1% pet 0.1% pet 0.1% pet 0.1% pet 
Budesonide 0.1% pet 0.01% pet 0.01% pet Not included 0.01% pet 
Tixocortol-21-pivalate 1% pet 0.1% pet 0.1% pet Not included 0.1% pet 
Black rubber mix 0.6% Not included Not included 0.6% pet Not included 
Disperse blue mix (124/106) Not included Not included Not included Not included 1% pet 
Propylene glycol 10% aq Not included Not included Not included 30% aq 
127 
 
Allergen Australian baseline 
series  
European baseline 
series 
International 
baseline series 
Japanese baseline 
series 
North American 
baseline series 
Benzyl alcohol 5% pet Not included Not included Not included Not included 
Tea tree oil 5% pet Not included Not included Not included Not included 
Diazolidinyl Urea  2% pet Not included 2% pet Not included 1% pet 
Primin Not included 0.01% pet Not included 0.01% pet Not included 
N-Isopropyl-N-phenyl-4-
phenylenediamine 
Not included 0.1% pet 0.1% pet Not included 0.1% pet 
Ethylenediamine dihydrochloride Not included Not included Not included Not included 1% pet 
Benzocaine 5% pet 5% pet Not included Not included 5% pet 
Methyl dibromoglutaronitrile Not included 0.5% pet 0.3% pet Not included 0.5% pet 
Lyral 5% pet 5% pet 5% pet Not included Not included 
Fragrance mix II  14% pet 14% pet 14% pet Not included 14% pet 
DMDM hydantoin 2% aq Not included Not included Not included 1% pet 
Compositae mix 6% pet Not included 6% pet Not included 5% pet 
Basic red 46 1% pet Not included Not included Not included Not included 
Coconut diethanolamide 0.5% pet Not included Not included Not included Not included 
Amerchol L 101 50% pet Not included Not included Not included 50% pet 
Cocaminopropyl betaine 1% aq Not included Not included Not included 1% aq 
Benzophenone 3 10% pet Not included Not included Not included 10% pet 
2-hydroxyethyl methacrylate 2% pet Not included Not included Not included Not included 
Chloroacetamide 0.2% pet Not included Not included Not included Not included 
Benzophenone 4 2% pet Not included Not included Not included Not included 
Cetylstearyl alcohol 20% pet Not included Not included Not included Not included 
Hydroperoxides of linalool 1% pet Not included Not included Not included Not included 
Hydroperoxides of limonene 1% pet Not included Not included Not included Not included 
Mixed dialkyl thiourea 1% pet Not included Not included Not included 1% pet 
Methylprednisolone aceponate cream  As is Not included Not included Not included Not included 
Benzalkonium chloride 0.1% pet Not included Not included Not included Not included 
Lidocaine 15% pet Not included Not included Not included Not included 
2-bromo-2-nitropropane-1,2-diol 
(bronopol) 
0.5% pet Not included Not included Not included 0.5% pet 
4-chloro-3,5-xylenol (PCMX) 1% pet Not included Not included Not included 1% pet 
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Allergen Australian baseline 
series  
European baseline 
series 
International 
baseline series 
Japanese baseline 
series 
North American 
baseline series 
Bufexamac 5% pet Not included Not included Not included Not included 
Betamethasone valerate 1% pet Not included Not included Not included Not included 
Ethylhexyl methoxycinnamate  10% pet Not included Not included Not included Not included 
Triamcinolone acetonide 1% pet Not included Not included Not included Not included 
Betamethasone dipropionate  0.5% pet Not included Not included Not included Not included 
Iodopropynyl butylcarbamate 0.2% pet Not included Not included Not included 0.2% pet 
Clioquinol Not included 5% pet Not included Not included Not included 
Textile dye mix 6.6% pet 6.6% pet Not included Not included Not included 
Hydrocortisone-17-butyrate Not included Not included 1% pet Not included 1% pet 
Dithiocarbamate mix Not included Not included Not included 2% pet Not included 
Gold sodium thiosulfate Not included Not included Not included 0.5% pet Not included 
Caine mix Not included Not included Not included 7% pet Not included 
Thiomersal Not included Not included Not included 0.05% pet Not included 
Petrolatum Not included Not included Not included 100% Not included 
Cinnamal Not included Not included Not included Not included 1% pet 
Bacitracin Not included Not included Not included Not included 20% pet 
Glutaral Not included Not included Not included Not included 0.5% pet 
Methyl methacrylate Not included Not included Not included Not included 2% pet 
Ethyleneurea melamine formaldehyde 
mix 
Not included Not included Not included Not included 5% pet 
Ethyl acrylate Not included Not included Not included Not included 0.1% pet 
Glyceryl thioglyconate Not included Not included Not included Not included 1% pet 
Dimethylol dihydroxy ethylene urea Not included Not included Not included Not included 4.5% aq 
Total number of allergens 60 30 32 24 60 
Pet = petrolatum; Aq = aqueous 
  
 Appendix four: Brief description of allergens in the Australian Baseline Series 
(ABS) 
 
Allergen Description 
Nickel sulfate Metal. Commonly found in jewellery, coins, keys, 
clothing items. Cellphones more recent source. 
Myroxylon pereirae Fragrance sourced from Myroxolon balsamum tree. 
Used as perfume, flavouring and in medicinal 
products due to mild antiseptic properties. 
Colophonium Resin sourced from pine tree. Used for sticky 
properties in numerous products including 
cosmetics, toiletries, adhesives, waxes, paper 
products, chewing gum. 
Diazolidinyl urea Formaldehyde releasing preservative used in 
toiletries and cosmetics. 
Paraphenylenediamine 
(PPD) 
Dark coloured dye commonly found in hair dye and 
also cosmetics, temporary tattoos and inks. 
2-Mercaptobenzothiazole 
(MBT) 
Additive found in rubber products. Also found in 
cutting oil, antifreeze and detergents. 
Formaldehyde Organic compound with multiple sources including 
fabrics, toiletries, cosmetics, paper and paint 
products, some medications. 
Potassium dichromate Chromium salt used in the manufacture of cement, 
leather and paints. 
Lanolin  Emulsifier obtained from wool of sheep. Used in 
moisturisers and cosmetics. 
Epoxy resin Part of a two-part epoxy adhesive system. Used as 
glue, electrical insulation and in production of 
polyvinyl chloride (PVC). 
Hydroperoxides of linalool Fragrance and flavour. 
Neomycin sulfate Antibacterial agent often used in topical 
preparations. 
Cobalt chloride Metal. Also used as blue pigment or light brown hair 
dye. 
Imidazolidinyl urea Formaldehyde releasing preservative used in 
toiletries and cosmetics. 
Cocamidoproyl betaine Surfactant (foaming agent) found in toiletries. 
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Allergen Description 
Paraben mix Preservative found in toiletries, cosmetics and 
topical medications. 
Thiuram mix Mix of chemicals used in rubber manufacturing 
(Tetramethylthiuramdisulfide, Tetramethylthiuram 
monosulfide and Tetraethylthiuram disulfide) 
Mercapto mix Mix of chemicals used in rubber manufacturing (2-
(4-Morpholinylmercapto)benzothiazol, 
Dibenzothiazyl disulfide, N-Cyclohexyl-2-
benzothiazolesulfenamide, 2-
Mercaptobenzothiazole). 
Fragrance mix I Mix of fragrances (Cinnamyl alcohol, Cinnamal, 
Hydroxycitronellal, Amyl cinnamal, Gernaiol, 
Eugenol, Isoeugenol, Oakmoss absolute). 
Fragrance mix II Mix of fragrances (Hexyl cinnamic aldehyde, 
Hydroxyisohexyl 3-cyclohexene carboxadehyde, 
Farnesol, Coumarin, Citral, Citronellol). 
Black rubber mix Mix of rubber antidegradants (N-Cyclohexyl-N-
phenyl-4-phenelenediamine, N,N’-diphenyl-p-
phenylenediamine, N-isopropyl-N-phenyl-4-
phenylenediamine. 
MCI/MI Preservative containing methylisothiazolinone and 
methylchloroisothiazolinone. Found in toiletries and 
cosmetics, especially shampoos and conditioners. 
Sesquiterpene lactone mix Mix of isolates from compositae plants (a cause of 
plant dermatitis). 
4-tert-butylphenol-
formaldehyde resin (PTBP) 
Resin used in adhesives. 
Tolenesulfonamide 
formaldehyde resin 
Adhesion promoter found in nail polish and acrylics. 
Quaternium 15 Formaldehyde releasing preservative used in 
toiletries and cosmetics. 
Tixocortol-21-pivalate Marker for group A corticosteroid allergy. 
Benzocaine Anaesthetic found in topical medicaments. 
Budesonide Marker for group B corticosteroid allergy. 
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Allergen Description 
Propylene glycol Synthetic organic compound used in production of 
polymers, antifreeze and solvent in foods. 
Basic red 46 Textile dye. 
Benzyl alcohol Solvent and preservative with multiple sources 
including photographic developers, cosmetics, 
perfumes, toiletries, foods, plastics and inks. 
Tea tree oil oxidised Antiseptic isolated from Melaleuca tree. 
Cetearyl alcohol Emulsifier and emollient used in cosmetics and 
toiletries. Mix of cetyl and stearyl alcohols. 
Compositae mix II Mix of isolates from compositae plants (a cause of 
plant dermatitis). 
4-Chloro-3-cresol Emollient and lubricant found in toiletries, cosmetics 
and medicaments. 
Chloroacetamide Preservative found in cosmetics, toiletries, glues 
and cooling fluids. 
Methylprednisolone 
aceponate 
Topical corticosteroid. 
Mixed dialkyl thiourea Component of neoprene rubber. 
Cocamide DEA Surfactant (foaming agent) in toiletries. 
DMDM hydantoin Formaldehyde releasing preservative used in 
toiletries and cosmetics. 
Carba mix Mix of rubber activators and accelerators (1,3-
Diphenylguanidine, Zinc diethyldithiocarbamate, 
Zinc dibutyldithiocarbamate). 
Benzophenone 3 Sunscreen. 
Benzophenone 4 Sunscreen. 
Hydroxyisohexyl 3-
cyclohexene 
carboxaldehyde (Lyral) 
Floral fragrance. 
Hydroperoxides of limonene Fragrance and flavour. 
Textile dye mix Mix of disperse dyes used for fabric (disperse blue 
35, disperse orange 1, disperse orange 3, disperse 
red 1, disperse red 17, disperse yellow 3, disperse 
blue 106, disperse blue 124). 
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Allergen Description 
Benzalkonium chloride Antiseptic agent used in cosmetics, toiletries and 
topical medicaments. 
Lidocaine Anaesthetic found in topical medicaments. 
Chloroxylenol (PCMX) Preservative used in topical antiseptics. 
Amerchol L-101 Emulsifier and emollient containing lanolin alcohols. 
Used in toiletries, cosmetics, waxes and polishes. 
Betamethasone 
diopropionate 
Topical corticosteroid. 
Bufexamac Anti-inflammatory used in topical medicaments 
including haemorrhoid suppositories. 
Ethylhexyl 
methoxycinnamate 
Sunscreen. 
2-Bromo-2-nitropropane-
1,3-diol 
Bactericidal agent used in cosmetics, toiletries and 
topical medicaments. 
Betamethasone valerate Topical corticosteroid. 
2-Hydroxyethyl 
methacrylate (HEMA) 
Methacrylate adhesive. Found in artificial nails. 
Triamcinolone acetonide Topical corticosteroid. 
Iodopropynyl 
butylcarbamate 
Bactericide and fungicide in wood, paint and cooling 
fluids. 
Methylisothiazolinone Preservative found in toiletries and cosmetics, 
especially shampoos and conditioners. 
 Appendix five: Results of patch testing at The Skin Hospitals in Darlinghurst and Westmead from 1/01/07 to 31/12/16  
Allergen Total (n=1584) Darlinghurst (n=579) Westmead (n=1005) 
Tested Positive Relevant Positive/ 
tested % 
Positive/ 
total % 
Relevant/ 
tested % 
Relevant/ 
total % 
Tested Positive Relevant Positive/ 
tested% 
Positive/ 
total % 
Relevant/ 
tested % 
Relevant/ 
total % 
Tested Positive Relevant Positive/
tested% 
Positive/ 
total % 
Relevant/ 
tested % 
Relevant/ 
total % 
Own products total 1102 162 74 14.7 10.2 6.7 4.7 253 28 25 11.1 4.8 9.9 4.3 849 134 49 15.8 13.3 5.8 4.9 
Nickel sulfate 1559 119 18 7.6 7.5 1.2 1.1 575 23 11 4.0 4.0 1.9 1.9 984 96 7 9.8 9.6 0.7 0.7 
Cobalt chloride 1559 59 7 3.8 3.7 0.4 0.4 575 10 4 1.7 1.7 0.7 0.7 984 49 3 5.0 4.9 0.3 0.3 
Myroxylon pereirae 886 58 16 6.5 3.7 1.8 1.0 574 4 4 0.7 0.7 0.7 0.7 312 54 12 17.3 5.4 3.8 1.2 
Fragrance mix I 1559 55 21 3.5 3.5 1.3 1.3 574 5 4 0.9 0.9 0.7 0.7 985 50 17 5.1 5.0 1.7 1.7 
p-Phenylenediamine 1564 41 28 2.6 2.6 1.8 1.8 579 8 5 1.4 1.4 0.9 0.9 985 33 23 3.4 3.3 2.3 2.3 
Potassium dichromate 1557 39 8 2.5 2.5 0.5 0.5 574 5 2 0.9 0.9 0.3 0.3 983 34 6 3.5 3.4 0.6 0.6 
MCI/MI 886 31 20 3.5 2.0 2.3 1.3 573 3 2 0.5 0.5 0.3 0.3 313 28 18 8.9 2.8 5.8 1.8 
Dodecyl gallate  1182 31 11 2.6 2.0 0.9 0.7 525 20 11 3.8 3.5 2.1 1.9 657 11 0 1.7 1.1 0.0 0.0 
Colophonium 1561 27 9 1.7 1.7 0.6 0.6 575 6 6 1.0 1.0 1.0 1.0 986 21 3 2.1 2.1 0.3 0.3 
Thiuram mix 1561 22 12 1.4 1.4 0.8 0.8 575 5 3 0.9 0.9 0.5 0.5 986 17 9 1.7 1.7 0.9 0.9 
Methylisothiazolinone 155 21 16 13.5 1.3 10.3 1.0 33 5 3 15.2 0.9 9.1 0.5 122 16 13 13.1 1.6 10.7 1.3 
Thiomersal  685 21 1 3.1 1.3 0.1 0.1 27 0 0 0.0 0.0 0.0 0.0 658 21 1 3.2 2.1 0.2 0.1 
Quaternium 15 1561 17 7 1.1 1.1 0.4 0.4 574 5 3 0.9 0.9 0.5 0.5 987 12 4 1.2 1.2 0.4 0.4 
Carba Mix 1559 15 4 1.0 0.9 0.3 0.3 574 3 2 0.5 0.5 0.3 0.3 985 12 2 1.2 1.2 0.2 0.2 
Methyldibromo Glutaronitrile 1511 14 5 0.9 0.9 0.3 0.3 526 6 5 1.1 1.0 1.0 0.9 985 8 0 0.8 0.8 0.0 0.0 
Sodium metabisulfite   738 14 1 1.9 0.9 0.1 0.1 82 1 0 1.2 0.2 0.0 0.0 656 13 1 2.0 1.3 0.2 0.1 
Formaldehyde 1559 12 5 0.8 0.8 0.3 0.3 574 3 3 0.5 0.5 0.5 0.5 985 9 2 0.9 0.9 0.2 0.2 
25-Diaminotoluene sulfate 85 11 8 12.9 0.7 9.4 0.5 1 0 0 0.0 0.0 0.0 0.0 84 11 8 13.1 1.1 9.5 0.8 
Toluenesulfonamide 
formaldehyde resin 
1561 11 5 0.7 0.7 0.3 0.3 575 5 3 0.9 0.9 0.5 0.5 986 6 2 0.6 0.6 0.2 0.2 
Ammonium persulfate 129 10 7 7.8 0.6 5.4 0.4 45 1 1 2.2 0.2 2.2 0.2 84 9 6 10.7 0.9 7.1 0.6 
Epoxy resin 1558 10 2 0.6 0.6 0.1 0.1 573 3 1 0.5 0.5 0.2 0.2 985 7 1 0.7 0.7 0.1 0.1 
Tea tree oil 573 10 6 1.7 0.6 1.0 0.4 573 10 6 1.7 1.7 1.0 1.0 0 0 0 . 0.0 . 0.0 
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Allergen Total (n=1584) Darlinghurst (n=579) Westmead (n=1005) 
Tested Positive Relevant Positive/ 
tested % 
Positive/ 
total % 
Relevant/ 
tested % 
Relevant/ 
total % 
Tested Positive Relevant Positive/ 
tested% 
Positive/ 
total % 
Relevant/ 
tested % 
Relevant/ 
total % 
Tested Positive Relevant Positive/
tested% 
Positive/ 
total % 
Relevant/ 
tested % 
Relevant/ 
total % 
Benzophenone 3 354 10 6 2.8 0.6 1.7 0.4 96 1 1 1.0 0.2 1.0 0.2 258 9 5 3.5 0.9 1.9 0.5 
Cinnamic alcohol 440 9 7 2.0 0.6 1.6 0.4 135 2 2 1.5 0.3 1.5 0.3 305 7 5 2.3 0.7 1.6 0.5 
Octyl gallate   1098 9 0 0.8 0.6 0.0 0.0 444 5 0 1.1 0.9 0.0 0.0 654 4 0 0.6 0.4 0.0 0.0 
Chloroacetamide 851 8 0 0.9 0.5 0.0 0.0 174 0 0 0.0 0.0 0.0 0.0 677 8 0 1.2 0.8 0.0 0.0 
Parabens mix 1561 8 5 0.5 0.5 0.3 0.3 574 5 3 0.9 0.9 0.5 0.5 987 3 2 0.3 0.3 0.2 0.2 
Coconut diethanolamide 1015 7 2 0.7 0.4 0.2 0.1 446 0 0 0.0 0.0 0.0 0.0 569 7 2 1.2 0.7 0.4 0.2 
Diazolidinyl Urea 998 7 5 0.7 0.4 0.5 0.3 428 3 2 0.7 0.5 0.5 0.3 570 4 3 0.7 0.4 0.5 0.3 
Mercapto mix 1561 7 4 0.4 0.4 0.3 0.3 575 2 2 0.3 0.3 0.3 0.3 986 5 2 0.5 0.5 0.2 0.2 
Neomycin sulfate 1560 7 1 0.4 0.4 0.1 0.1 574 3 0 0.5 0.5 0.0 0.0 986 4 1 0.4 0.4 0.1 0.1 
Oakmoss absolute 440 7 4 1.6 0.4 0.9 0.3 135 0 0 0.0 0.0 0.0 0.0 305 7 4 2.3 0.7 1.3 0.4 
Basic red 46 253 6 5 2.4 0.4 2.0 0.3 119 5 4 4.2 0.9 3.4 0.7 134 1 1 0.7 0.1 0.7 0.1 
Benzalkonium chloride 680 6 0 0.9 0.4 0.0 0.0 23 0 0 0.0 0.0 0.0 0.0 657 6 0 0.9 0.6 0.0 0.0 
Benzocaine 1354 6 2 0.4 0.4 0.1 0.1 369 1 0 0.3 0.2 0.0 0.0 985 5 2 0.5 0.5 0.2 0.2 
Disperse blue mix (124/106) 693 6 2 0.9 0.4 0.3 0.1 573 5 1 0.9 0.9 0.2 0.2 120 1 1 0.8 0.1 0.8 0.1 
Geraniol 440 6 2 1.4 0.4 0.5 0.1 135 0 0 0.0 0.0 0.0 0.0 305 6 2 2.0 0.6 0.7 0.2 
Imidazolidinyl urea 1562 6 2 0.4 0.4 0.1 0.1 574 2 0 0.3 0.3 0.0 0.0 988 4 2 0.4 0.4 0.2 0.2 
Isoeugenol 440 6 2 1.4 0.4 0.5 0.1 135 0 0 0.0 0.0 0.0 0.0 305 6 2 2.0 0.6 0.7 0.2 
Paratertiarybutyl phenol 
formaldehyde 
574 6 5 1.0 0.4 0.9 0.3 574 6 5 1.0 1.0 0.9 0.9 0 0 0 . 0.0 . 0.0 
Lanolin 1559 6 2 0.4 0.4 0.1 0.1 574 2 1 0.3 0.3 0.2 0.2 985 4 1 0.4 0.4 0.1 0.1 
Cinnamic aldehyde 440 5 4 1.1 0.3 0.9 0.3 135 2 2 1.5 0.3 1.5 0.3 305 3 2 1.0 0.3 0.7 0.2 
Limonene 477 5 2 1.0 0.3 0.4 0.1 155 0 0 0.0 0.0 0.0 0.0 322 5 2 1.6 0.5 0.6 0.2 
N-Methylol chloroacetamide 696 5 3 0.7 0.3 0.4 0.2 20 0 0 0.0 0.0 0.0 0.0 676 5 3 0.7 0.5 0.4 0.3 
Sodium benzoate 675 5 0 0.7 0.3 0.0 0.0 22 0 0 0.0 0.0 0.0 0.0 653 5 0 0.8 0.5 0.0 0.0 
2-Nitro-4-phenylenediamine 130 4 4 3.1 0.3 3.1 0.3 47 1 1 2.1 0.2 2.1 0.2 83 3 3 3.6 0.3 3.6 0.3 
4-Aminoazobenzene 233 4 2 1.7 0.3 0.9 0.1 104 0 0 0.0 0.0 0.0 0.0 129 4 2 3.1 0.4 1.6 0.2 
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Allergen Total (n=1584) Darlinghurst (n=579) Westmead (n=1005) 
Tested Positive Relevant Positive/ 
tested % 
Positive/ 
total % 
Relevant/ 
tested % 
Relevant/ 
total % 
Tested Positive Relevant Positive/ 
tested% 
Positive/ 
total % 
Relevant/ 
tested % 
Relevant/ 
total % 
Tested Positive Relevant Positive/
tested% 
Positive/ 
total % 
Relevant/ 
tested % 
Relevant/ 
total % 
4-Aminophenol 188 4 3 2.1 0.3 1.6 0.2 105 1 1 1.0 0.2 1.0 0.2 83 3 2 3.6 0.3 2.4 0.2 
Chloro xylenol 657 4 2 0.6 0.3 0.3 0.1 1 0 0 0.0 0.0 0.0 0.0 656 4 2 0.6 0.4 0.3 0.2 
2 Hydroxyethyl methacrylate 192 4 2 2.1 0.3 1.0 0.1 1 0 0 0.0 0.0 0.0 0.0 191 4 2 2.1 0.4 1.0 0.2 
Budesonide 678 4 0 0.6 0.3 0.0 0.0 574 4 0 0.7 0.7 0.0 0.0 104 0 0 0.0 0.0 0.0 0.0 
Cocamidopropyl betaine 972 4 2 0.4 0.3 0.2 0.1 403 3 2 0.7 0.5 0.5 0.3 569 1 0 0.2 0.1 0.0 0.0 
Disperse blue 106 235 4 3 1.7 0.3 1.3 0.2 105 3 2 2.9 0.5 1.9 0.3 130 1 1 0.8 0.1 0.8 0.1 
Glutaraldehyde  104 4 1 3.8 0.3 1.0 0.1 22 0 0 0.0 0.0 0.0 0.0 82 4 1 4.9 0.4 1.2 0.1 
Glyceryl monothioglycolate 128 4 1 3.1 0.3 0.8 0.1 46 0 0 0.0 0.0 0.0 0.0 82 4 1 4.9 0.4 1.2 0.1 
Hexylresorcinol 655 4 0 0.6 0.3 0.0 0.0 0 0 0 . 0.0 . 0.0 655 4 0 0.6 0.4 0.0 0.0 
Lyral 440 4 2 0.9 0.3 0.5 0.1 135 0 0 0.0 0.0 0.0 0.0 305 4 2 1.3 0.4 0.7 0.2 
2-Mercaptobenzothiazole 991 4 1 0.4 0.3 0.1 0.1 6 0 0 0.0 0.0 0.0 0.0 985 4 1 0.4 0.4 0.1 0.1 
Palladium Chloride 66 4 1 6.1 0.3 1.5 0.1 1 0 0 0.0 0.0 0.0 0.0 65 4 1 6.2 0.4 1.5 0.1 
Pyrogallol 84 4 2 4.8 0.3 2.4 0.1 0 0 0 . 0.0 . 0.0 84 4 2 4.8 0.4 2.4 0.2 
13 Diphenylguanidine 176 3 1 1.7 0.2 0.6 0.1 164 2 1 1.2 0.3 0.6 0.2 12 1 0 8.3 0.1 0.0 0.0 
Benzophenone 4 225 3 2 1.3 0.2 0.9 0.1 96 0 0 0.0 0.0 0.0 0.0 129 3 2 2.3 0.3 1.6 0.2 
3-Aminophenol 203 3 2 1.5 0.2 1.0 0.1 1 0 0 0.0 0.0 0.0 0.0 202 3 2 1.5 0.3 1.0 0.2 
4-tert-Butylphenol 
formaldehyde resin 
986 3 1 0.3 0.2 0.1 0.1 1 0 0 0.0 0.0 0.0 0.0 985 3 1 0.3 0.3 0.1 0.1 
Cetyl alcohol 873 3 3 0.3 0.2 0.3 0.2 303 0 0 0.0 0.0 0.0 0.0 570 3 3 0.5 0.3 0.5 0.3 
Copper sulfate 96 3 0 3.1 0.2 0.0 0.0 1 0 0 0.0 0.0 0.0 0.0 95 3 0 3.2 0.3 0.0 0.0 
Disperse orange 3 237 3 2 1.3 0.2 0.8 0.1 104 0 0 0.0 0.0 0.0 0.0 133 3 2 2.3 0.3 1.5 0.2 
Epoxy acrylate 985 3 0 0.3 0.2 0.0 0.0 0 0 0 . 0.0 . 0.0 985 3 0 0.3 0.3 0.0 0.0 
Ethylenediamine 
dihydrochloride 
1511 3 1 0.2 0.2 0.1 0.1 526 0 0 0.0 0.0 0.0 0.0 985 3 1 0.3 0.3 0.1 0.1 
Melamine formaldehyde 663 3 1 0.5 0.2 0.2 0.1 575 0 0 0.0 0.0 0.0 0.0 88 3 1 3.4 0.3 1.1 0.1 
Mercury 107 3 1 2.8 0.2 0.9 0.1 13 1 1 7.7 0.2 7.7 0.2 94 2 0 2.1 0.2 0.0 0.0 
N-Isopropyl-N-phenyl-4-
phenylenediamine 
1119 3 0 0.3 0.2 0.0 0.0 134 0 0 0.0 0.0 0.0 0.0 985 3 0 0.3 0.3 0.0 0.0 
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Sorbic Acid  1049 3 0 0.3 0.2 0.0 0.0 394 1 0 0.3 0.2 0.0 0.0 655 2 0 0.3 0.2 0.0 0.0 
Sorbitan sesquioleate 948 3 3 0.3 0.2 0.3 0.2 381 2 2 0.5 0.3 0.5 0.3 567 1 1 0.2 0.1 0.2 0.1 
2-Bromo-2-nitropropane-13-
diol 
658 2 1 0.3 0.1 0.2 0.1 1 0 0 0.0 0.0 0.0 0.0 657 2 1 0.3 0.2 0.2 0.1 
Advantan cream 284 2 0 0.7 0.1 0.0 0.0 180 0 0 0.0 0.0 0.0 0.0 104 2 0 1.9 0.2 0.0 0.0 
Advantan ointment 283 2 0 0.7 0.1 0.0 0.0 180 0 0 0.0 0.0 0.0 0.0 103 2 0 1.9 0.2 0.0 0.0 
Chlorhexidine digluconate  736 2 0 0.3 0.1 0.0 0.0 81 0 0 0.0 0.0 0.0 0.0 655 2 0 0.3 0.2 0.0 0.0 
Dermaphagoides mix 3 2 1 66.7 0.1 33.3 0.1 3 2 1 66.7 0.3 33.3 0.2 0 0 0 . 0.0 . 0.0 
Desonide 103 2 0 1.9 0.1 0.0 0.0 1 0 0 0.0 0.0 0.0 0.0 102 2 0 2.0 0.2 0.0 0.0 
Disperse orange 1 121 2 1 1.7 0.1 0.8 0.1 0 0 0 . 0.0 . 0.0 121 2 1 1.7 0.2 0.8 0.1 
Disperse Red 1 233 2 2 0.9 0.1 0.9 0.1 104 1 1 1.0 0.2 1.0 0.2 129 1 1 0.8 0.1 0.8 0.1 
DMDM Hydantoin 374 2 1 0.5 0.1 0.3 0.1 374 2 1 0.5 0.3 0.3 0.2 0 0 0 . 0.0 . 0.0 
Ethyleneglycol dimethacrylate  201 2 1 1.0 0.1 0.5 0.1 10 0 0 0.0 0.0 0.0 0.0 191 2 1 1.0 0.2 0.5 0.1 
Eugenol 477 2 0 0.4 0.1 0.0 0.0 143 0 0 0.0 0.0 0.0 0.0 334 2 0 0.6 0.2 0.0 0.0 
Hydroxycitronellal 305 2 0 0.7 0.1 0.0 0.0 0 0 0 . 0.0 . 0.0 305 2 0 0.7 0.2 0.0 0.0 
Methyl methacrylate  208 2 1 1.0 0.1 0.5 0.1 10 0 0 0.0 0.0 0.0 0.0 198 2 1 1.0 0.2 0.5 0.1 
Peppermint oil 378 2 1 0.5 0.1 0.3 0.1 45 0 0 0.0 0.0 0.0 0.0 333 2 1 0.6 0.2 0.3 0.1 
Potassium dicyanoaurate 272 2 1 0.7 0.1 0.4 0.1 178 0 0 0.0 0.0 0.0 0.0 94 2 1 2.1 0.2 1.1 0.1 
Propylene glycol 579 2 1 0.3 0.1 0.2 0.1 10 0 0 0.0 0.0 0.0 0.0 569 2 1 0.4 0.2 0.2 0.1 
Urea formaldehyde  177 2 0 1.1 0.1 0.0 0.0 101 0 0 0.0 0.0 0.0 0.0 76 2 0 2.6 0.2 0.0 0.0 
Fragrance mix II 33 1 1 3.0 0.1 3.0 0.1 33 1 1 3.0 0.2 3.0 0.2 0 0 0 . 0.0 . 0.0 
135-Tris(2-
hydroxyethyl)hexahydrotriazine 
656 1 1 0.2 0.1 0.2 0.1 1 0 0 0.0 0.0 0.0 0.0 655 1 1 0.2 0.1 0.2 0.1 
16-Hexanedioldiglycidylether 32 1 1 3.1 0.1 3.1 0.1 32 1 1 3.1 0.2 3.1 0.2 0 0 0 . 0.0 . 0.0 
2-Bromo-2-nitropropane-13-
diol 
81 1 1 1.2 0.1 1.2 0.1 81 1 1 1.2 0.2 1.2 0.2 0 0 0 . 0.0 . 0.0 
3-(4-Methylbenzyliden) 
camphor 
126 1 0 0.8 0.1 0.0 0.0 0 0 0 . 0.0 . 0.0 126 1 0 0.8 0.1 0.0 0.0 
Chlorocresol 1583 1 0 0.1 0.1 0.0 0.0 595 0 0 0.0 0.0 0.0 0.0 988 1 0 0.1 0.1 0.0 0.0 
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4-tert-Butylphenol 73 1 0 1.4 0.1 0.0 0.0 0 0 0 . 0.0 . 0.0 73 1 0 1.4 0.1 0.0 0.0 
Amerchol L 101 81 1 1 1.2 0.1 1.2 0.1 81 1 1 1.2 0.2 1.2 0.2 0 0 0 . 0.0 . 0.0 
Castor oil 983 1 0 0.1 0.1 0.0 0.0 1 0 0 0.0 0.0 0.0 0.0 982 1 0 0.1 0.1 0.0 0.0 
Disperse blue 124 120 1 1 0.8 0.1 0.8 0.1 0 0 0 . 0.0 . 0.0 120 1 1 0.8 0.1 0.8 0.1 
Phenylbenzimidazole Sulfonic 
Acid 
104 1 1 1.0 0.1 1.0 0.1 104 1 1 1.0 0.2 1.0 0.2 0 0 0 . 0.0 . 0.0 
Sesquiterpene lactone mix 593 1 0 0.2 0.1 0.0 0.0 573 1 0 0.2 0.2 0.0 0.0 20 0 0 0.0 0.0 0.0 0.0 
Triclosan 1128 1 0 0.1 0.1 0.0 0.0 453 0 0 0.0 0.0 0.0 0.0 675 1 0 0.1 0.1 0.0 0.0 
1H-Benzotriazol 694 0 0 0.0 0.0 0.0 0.0 19 0 0 0.0 0.0 0.0 0.0 675 0 0 0.0 0.0 0.0 0.0 
2- Phenoxyethanol 256 0 0 0.0 0.0 0.0 0.0 81 0 0 0.0 0.0 0.0 0.0 175 0 0 0.0 0.0 0.0 0.0 
26-Di-tert-butyl-4-cresol 81 0 0 0.0 0.0 0.0 0.0 81 0 0 0.0 0.0 0.0 0.0 0 0 0 . 0.0 . 0.0 
2-Ethylhexyl acrylate 192 0 0 0.0 0.0 0.0 0.0 1 0 0 0.0 0.0 0.0 0.0 191 0 0 0.0 0.0 0.0 0.0 
Ethylhexyl methoxycinnamate  224 0 0 0.0 0.0 0.0 0.0 96 0 0 0.0 0.0 0.0 0.0 128 0 0 0.0 0.0 0.0 0.0 
2-Hydroxypropyl methacrylate 14 0 0 0.0 0.0 0.0 0.0 9 0 0 0.0 0.0 0.0 0.0 5 0 0 0.0 0.0 0.0 0.0 
2-n-Octyl-4-isothiazolin-3-one 12 0 0 0.0 0.0 0.0 0.0 0 0 0 . 0.0 . 0.0 12 0 0 0.0 0.0 0.0 0.0 
2-Phenylphenol 53 0 0 0.0 0.0 0.0 0.0 18 0 0 0.0 0.0 0.0 0.0 35 0 0 0.0 0.0 0.0 0.0 
4-Aminobenzoic acid (PABA) 224 0 0 0.0 0.0 0.0 0.0 96 0 0 0.0 0.0 0.0 0.0 128 0 0 0.0 0.0 0.0 0.0 
4-tert.Butyl-4'-methoxy-
dibenzoylmethane 
224 0 0 0.0 0.0 0.0 0.0 96 0 0 0.0 0.0 0.0 0.0 128 0 0 0.0 0.0 0.0 0.0 
4-tert.Butylcatechol 73 0 0 0.0 0.0 0.0 0.0 0 0 0 . 0.0 . 0.0 73 0 0 0.0 0.0 0.0 0.0 
Amalagam Alloying Metals 94 0 0 0.0 0.0 0.0 0.0 0 0 0 . 0.0 . 0.0 94 0 0 0.0 0.0 0.0 0.0 
Aristocort cream 104 0 0 0.0 0.0 0.0 0.0 1 0 0 0.0 0.0 0.0 0.0 103 0 0 0.0 0.0 0.0 0.0 
Aristocort ointment 105 0 0 0.0 0.0 0.0 0.0 1 0 0 0.0 0.0 0.0 0.0 104 0 0 0.0 0.0 0.0 0.0 
Benzoyl peroxide 59 0 0 0.0 0.0 0.0 0.0 14 0 0 0.0 0.0 0.0 0.0 45 0 0 0.0 0.0 0.0 0.0 
Benzyl alcohol 1232 0 0 0.0 0.0 0.0 0.0 576 0 0 0.0 0.0 0.0 0.0 656 0 0 0.0 0.0 0.0 0.0 
Benzyl salicylate 81 0 0 0.0 0.0 0.0 0.0 81 0 0 0.0 0.0 0.0 0.0 0 0 0 . 0.0 . 0.0 
Betnovate Cream 104 0 0 0.0 0.0 0.0 0.0 1 0 0 0.0 0.0 0.0 0.0 103 0 0 0.0 0.0 0.0 0.0 
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Betnovate ointment 104 0 0 0.0 0.0 0.0 0.0 1 0 0 0.0 0.0 0.0 0.0 103 0 0 0.0 0.0 0.0 0.0 
Black rubber mix 574 0 0 0.0 0.0 0.0 0.0 574 0 0 0.0 0.0 0.0 0.0 0 0 0 . 0.0 . 0.0 
Compositae mix 0 0 0 . 0.0 . 0.0 0 0 0 . 0.0 . 0.0 0 0 0 . 0.0 . 0.0 
Diprosone cream 104 0 0 0.0 0.0 0.0 0.0 0 0 0 . 0.0 . 0.0 104 0 0 0.0 0.0 0.0 0.0 
Diprosone ointment 103 0 0 0.0 0.0 0.0 0.0 0 0 0 . 0.0 . 0.0 103 0 0 0.0 0.0 0.0 0.0 
Petrolatum 870 0 0 0.0 0.0 0.0 0.0 300 0 0 0.0 0.0 0.0 0.0 570 0 0 0.0 0.0 0.0 0.0 
Shellac 84 0 0 0.0 0.0 0.0 0.0 84 0 0 0.0 0.0 0.0 0.0 0 0 0 . 0.0 . 0.0 
Tixocortol-21-pivalate 678 0 0 0.0 0.0 0.0 0.0 574 0 0 0.0 0.0 0.0 0.0 104 0 0 0.0 0.0 0.0 0.0 
Mixed dialkyl thiourea 56 0 0 0.0 0.0 0.0 0.0 56 0 0 0.0 0.0 0.0 0.0 0 0 0 . 0.0 . 0.0 
Betamethasone diproprionate 400 0 0 0.0 0.0 0.0 0.0 355 0 0 0.0 0.0 0.0 0.0 45 0 0 0.0 0.0 0.0 0.0 
Tocopherol 81 0 0 0.0 0.0 0.0 0.0 81 0 0 0.0 0.0 0.0 0.0 0 0 0 . 0.0 . 0.0 
TOTALS . 1112 417 . . . . . 232 145 . . . . . 880 272 . . . . 
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